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1. INTRODUCTION
Antimalarial drug resistance has emerged as a leading threat to ongoing malaria control
efforts. As resistance to one or more antimalarial drugs occurs more frequently, malaria control
programmes and other concerned institutions need to be able to evaluate antimalarial drug
efficacy in a way that provides timely, relevant, reliable, and understandable information.
Data derived from these evaluations
are essential not only for maintaining
confidence that current treatment
recommendations are adequate in
relation to malaria patients’ needs,
but also, should that not be the case,
for generating convincing evidence that
current treatment recommendations
are in need of change. When such
evaluations are conducted consistently
over time and in a reasonable and
representative selection of sites,
programmes should be able to monitor
drug efficacy in a way that will allow
changes in treatment recommendations
or policies to be made early enough
to minimize the impact of a failing
treatment regimen.
The primary goal of this protocol is
to provide guidance in obtaining the
minimum essential information about
the clinical and parasitological response
to antimalarial drugs among populations
at greatest risk of severe morbidity or
mortality due to malaria. The intended
use of this protocol, therefore, is primarily
as a tool for the collection of clinically
relevant information for developing
evidence-based antimalarial treatment
policy. It is not intended for use as a more
traditional biomedical research protocol
and is not intended to replace well-
designed clinical trials conducted under
Good Clinical Practice (GCP) guidelines,
as should be done when investigating
new treatment lacking an adequate
history of safe clinical use.
Considerable emphasis has been placed
on maintaining as much simplicity and
practicality as possible. Using this protocol,
programmes lacking access to substantial
financial resources or to state-of-the-art
laboratory analysis — most often obtained
through collaborative links with medical
research institutions — should nonetheless
be able to produce the information
needed to ensure the best malaria
treatment for the people living
in their country. Programmes that do
have adequate resources and expertise
are encouraged to collect any additional
information that they feel is relevant.
However, they are also encouraged to
at least collect this minimal data set in
a way that is consistent with this protocol.
Only through such standardization will
it be possible to compare and interpret
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2. BACKGROUND
2.1 Development of the WHO
standardized in vivo test
The first well-documented reports of
Plasmodium falciparum resistant to
chloroquine were made between 1957
and 1960 in South-East Asia and South
America (1, 2). Because chloroquine
had become the treatment of choice for
malaria since its discovery in the 1930s,
there was a clear need to be able to
assess the extent of resistance to this
drug in areas where malaria was being
transmitted.
A standardized in vivo test system for
assessing the response of P. falciparum
to chloroquine was first developed in
1965 (3). This system was officially
revised twice, first in 1967 and again
in 1972 (4, 5). The methodology
that evolved from these revisions was
fairly demanding, requiring daily blood
examinations during the first week
post-treatment followed by a prolonged
period (28 days) of monitoring with
weekly blood examinations. Because
the outcome of primary interest was
reappearance of parasites within the
observation period, indicating treatment
failure, patients were kept in a mosquito-
free environment to prevent reinfection.
Later modifications allowed for a choice
between a shortened observation period
of 7 days (the “WHO standard test”)
and the longer 28-day observation period
(the “extended test”), depending on
whether the possibility of reinfection could
be excluded. The short observation period
allowed the test to be conducted under
typical field conditions and constraints.
In practice, individual researchers
have made numerous variations and
modifications. Unofficial modifications
of the protocol began to show the
usefulness of tracking clinical response
to treatment, including calculating fever
clearance times, initial symptom resolution,
time to reappearance of parasites,
and haematological response (6–9).
Because of the growing emphasis on
clinical response, these developments
began to take into account such issues
as the potential implications underlying
acquired immunity and the appropriateness
of inclusion of asymptomatic subjects.
As a result, there was a movement
towards including only symptomatic
patients in the test and, in areas of intense
transmission, focusing on the age group
at greatest risk of severe morbidity
and mortality (and least likely to have
a well developed immune response to
malaria), i.e. children less than 5 years
of age. There was also a move away
from the short, 7-day observation periods
towards observation periods of sufficient
length to allow observation of changes
in clinical and haematological status
(14 days or more).
These efforts culminated in a new
standardized protocol jointly developed
by the Centers for Disease Control and
Prevention, Atlanta, USA, and WHO
at an inter-country workshop – Malaria
Treatment and Resistance in Kenya,
Zambia and Malawi – in Mangochi,
Malawi, in 1996 (10).
During the same period, a second protocol
was developed specifically for areas of low
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to moderate transmission, beginning
with a meeting in Manila (Philippines)
in 1996 and continuing at an expert
meeting in Manaus (Brazil) in 1998 (11).
Recommendations resulting from a
meeting in Phnom Penh (Cambodia)
in 2000 (12) achieved further
refinement of the protocol.
Unfortunately, while these protocols
responded to different programmatic
priorities dictated by differences in the
underlying epidemiology of malaria, the
existence of two “official” protocols caused
some confusion. Most importantly, while
the two protocols used the same terms
to classify treatment failures, the actual
definitions of the terms differed between
areas of intense transmission and areas
of low to moderate transmission.
Consequently, if the protocols were
applied as recommended, results could
not be compared between different areas
of the world – or even within single countries
with highly variable transmission rates.
The protocol presented here is an attempt
to reconcile these protocols and produce
a single, globally standardized protocol.
Additionally, some methodological
problems that became apparent while
the 1996 protocol was in use have been
corrected. Modifications to the 1996
protocol were discussed and agreed
upon during an informal consultation
in Geneva in 2001 (13).
The objectives of this consultation were:
• to review and update the existing WHO
protocols for assessing the therapeutic
efficacy of drugs for treatment of
uncomplicated falciparum malaria
in areas with intense transmission (10)
and in areas with low to moderate
transmission (which exist only in
draft form);
• to review the draft guidelines for
assessing the therapeutic efficacy
of chloroquine against P. vivax;
• to review the potential role of in vitro
tests and current molecular methods for
detecting markers of resistance in the
surveillance of resistance to antimalarial
drugs; and
• to define the technical and operational
elements needed for strengthening
surveillance of drug resistance of both
falciparum and vivax malaria at the
country level.
2.2 Importance of in vivo tests
to antimalarial treatment policy
development
While treatment efficacy data represent
only one element in a wide array of
information needed to develop evidence-
based policy for treatment of malaria,
the results of in vivo tests conducted
using the WHO standardized in vivo
methodology are clearly critical.
Throughout Africa, south America, and
Asia, studies using the WHO in vivo
methodology have provided valuable
information on the efficacy of antimalarial
drugs in current use as well as initial
evaluations of potential alternative
treatment regimens.
In South-East Asia, Thailand has seen
the greatest change in treatment policies,
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in part because of the rapidity with which
resistance developed in that country.
Since 1973, Thailand has changed first-
line malaria treatment from chloroquine,
to sulfadoxine–pyrimethamine (SP) plus
mefloquine, to mefloquine alone, and
finally to a combination of mefloquine
and artesunate (14). Nearly all countries
in South-East Asia have either recently
changed first-line treatment recommendations
for malaria and are using in vivo studies
to monitor treatment efficacy prospectively,
or are in the process of evaluating
the efficacy of their current treatment
recommendations as a first step towards
potential change (12).
Chloroquine resistance was first reported
in east Africa in 1978 and spread
throughout the continent over the next
10 years. As resistance intensified,
especially in east Africa, concern began
to grow that treatment policies would
need to eventually change in favour
of more efficacious drugs.
Although the problem of failing chloroquine
efficacy was fully appreciated by medical
researchers in Africa, this appreciation was
slow to develop among those responsible
for formulating national malaria treatment
policy (15). Doubtless, there were many
reasons for this slow change in attitude,
but it was clear that decision-makers,
who did not necessarily have biomedical
research, or even medical, backgrounds,
either did not fully understand the
implications of parasitological failure or
were otherwise unconvinced by the data.
This situation was further complicated by
the fact that, owing to acquired immunity
and the antipyretic effect of chloroquine,
patients treated with chloroquine appeared
to get better even when parasites remained
or returned.
As the in vivo protocol evolved to focus
more on clinical outcomes, increased
emphasis was also placed on identifying
how best to communicate efficacy data
to policy-makers in ways that were
understandable, accessible, and convincing.
Although South Africa changed first-line
treatment from chloroquine to SP in one
province in 1988, primarily on the basis of
in vitro data, Malawi was the first country
in Africa to make the same change on a
national level. The impetus for this change
was a series of in vivo studies that clearly
showed high rates of chloroquine treatment
failure, the temporary nature of the initial
favourable clinical response to chloroquine
treatment, and the inadequate
haematological response to chlorquine,
compared with that to SP, among
anaemic children (16).
Since then, more African countries have
recognized the need for similar policy
changes. The advent and success of
multi-country subregional networks —
such as the East African Network for
Monitoring Antimalarial Treatment
(EANMAT) — have greatly increased
countries’ experience with and capacity
to conduct reliable in vivo studies. Similar
networks have developed elsewhere in
Africa, as well as in South-East Asia and
south America. As a result, in vivo efficacy
data have become more influential in
the development of national malaria
treatment policy (17).
9
3. OVERVIEW OF STUDY DESIGN
The fundamental design of this protocol
is intended to evaluate the therapeutic
efficacy of a range of antimalarial drugs
used for treating uncomplicated
falciparum malaria, providing the
minimum information essential for
programmatic decision-making. Studies
that follow this basic design, when
conducted periodically in a number
of appropriately selected sentinel sites,
can also form the basis of a surveillance
system capable of monitoring drug
efficacy changes over time.
The design is a simple, one-arm,
prospective evaluation of the clinical
and parasitological response to directly
observed treatment for uncomplicated
malaria. Additions to the protocol that
do not change its fundamental design
or intended purpose can be made and –
when technically and logistically feasible,
such as when measuring blood levels
of the drugs, extending the period of
follow-up, and testing for molecular
markers to help distinguish reinfection
from recrudescence – are even encouraged.
Programmes will probably wish to evaluate
more than one drug. For example, it is
common for programmes to evaluate
both the current first-line treatment as
well as one or more potential replacement
treatments. However, the protocol is not
designed for the evaluation of new or
experimental drugs; such studies, as well
as comparative clinical trials, usually require
design, ethical, and statistical considerations
that are beyond the scope of this protocol.
Furthermore, this protocol is not designed
to assess drug regimens administered over
periods longer than 3 days, such as quinine
(given for 7 days), combinations of quinine
and tetracycline or doxycycline (given over
7 days), or artemisinin monotherapy
(given for 5–7 days).
NOTE: Major changes to the 1996 protocol and the rationale
behind those changes are presented throughout in highlighted
text boxes such as this.
3. OVERVIEW OF STUDY DESIGN
10
ASSESSMENT AND MONITORING OF ANTIMALAIRAL DRUG EFFICACY FOR THE TREATMENT OF UNCOMPLICATED FALCIPARUM MALARIA
4. STUDY POPULATION
4.1 Target age group
In all areas, regardless of the intensity
of malaria transmission, the evaluation
of antimalarials for uncomplicated malaria
should emphasize treatment efficacy in
children < 5 years with clinically apparent
malaria. The rationale for this requirement
is that, even in populations with little
acquired immunity (as occurs in areas
of low or highly seasonal malaria
transmission), younger children often
have a less favourable therapeutic
response to antimalarial drugs than
do older children and adults. Obviously,
in areas of low malaria transmission,
exclusive enrolment of children < 5 years
is likely to pose logistic difficulties because
of the relative infrequency of malaria
infection in this age group. In such cases,
or in environments where young children
are at substantially lower risk of infection
than adults, such as occurs with
occupational exposure in some South-
East Asian countries, patients of all ages
can be enrolled. Nonetheless, wherever
possible, it is recommended that a
sufficient number of patients be enrolled
to allow for stratification of results based
on age (< 5 years and > 5 years).
4.2 Inclusion criteria
Patients should be selected on the
basis of the following criteria:
• Aged between 6 and 59 months
(but see comments on target age group
in section 4.1 above).
• Absence of severe malnutrition (defined
as a child whose weight-for-height is
below –3 standard deviation or less than
70% of the median of the NCHS/WHO
normalized reference values, or who
has symmetrical oedema involving at least
the feet) (18).
• A slide-confirmed infection with
P. falciparum only (i.e. no mixed infections).
• Initial parasite density. The range
of initial parasite densities appropriate
for inclusion differs by level of malaria
transmission intensity:
– for areas of low to moderate malaria
transmission, the acceptable range is
between 1000 and 100 000 asexual
parasites/µl;
– for areas of high transmission, the
acceptable range is between 2000 and
200 000 asexual parasites/µl.
NOTE: These recommended parasite
densities reflect a change from
the previous protocol. The
changes are supported by the
currently accepted definition
of hyperparasitaemia (19).
• Absence of general danger signs
among children < 5 years (see Box 1)
or other signs of severe and complicated
falciparum malaria according to current
WHO definitions (see Annex 1).
Box 1: GENERAL DANGER SIGNS
OF SEVERE ILLNESS
• Inability to drink or breastfeed
• Vomiting everything
• Recent history of convulsions
• Lethargy or unconsciousness
• Inability to sit or stand up
11• Measured axillary temperature ≥ 37.5 °Cor rectal/tympanic temperature ≥ 38.0 °C.
NOTE: Patients will no longer be
excluded on the basis of
a measured temperature
> 39.5 °C, in keeping with
the current definitions of severe
malaria (18). See Box 2 for a discussion
of the use of measured fever vs history
of fever.
• Ability to attend the stipulated follow-up
visits, and easy access to the health facility.
• Informed consent provided by patient
or parent/guardian (see example, Annex 2).
• Absence of history of hypersensitivity
reactions to any of the drugs being
evaluated. A history of adverse reactions
to antimalarials or other drugs is vital
medical information that should be
marked with a red pen or a highlighter
on the patient record form. While such
reactions to chloroquine, quinine, and
mefloquine are fairly rare and relatively
mild, reactions to drugs containing
sulfonamides may be life-threatening.
Life-threatening hypersensitivity reactions
to artemisinins have been described,
but appear to be very rare. In the case
of a history of allergic reactions to drugs,
the precise nature of which cannot be
determined, it is advisable to exclude the
patient from tests involving the suspect
drug(s) and to give the recommended
alternative treatment.
4.3 Exclusion criteria
In general, exclusion criteria are the
opposites of inclusion criteria. However,
some specific drugs have unique
exclusion criteria that must be taken into
account (although these are subject to
change, as data accumulate). For example,
for atovaquone–proguanil, artemether–
lumefantrine, and halofantrine there are
minimum age or weight cut-off points
below which treatment is not recommended.
Additionally, for studies allowing the
inclusion of patients > 5 years, other
exclusion criteria may be required, such
as pregnancy or lactation or the existence
of underlying chronic severe illness (e.g.
cardiac, renal, hepatic diseases, HIV/AIDS).
A history of previous antimalarial drug use
or the presence of antimalarial drugs in the
urine or blood is not an exclusion criterion.
Because, in many settings, prior anti-
malarial treatment is the rule rather than
the exception, exclusion of previously
treated patients would not yield a
representative sample of the target
population (i.e. patients attending health
facilities for the treatment of uncomplicated
malaria). In many settings it has also
been shown that antimalarial drugs can
be found in the blood or urine of patients
who deny previous use of antimalarial
drugs, suggesting that a history of
previous treatment is unreliable.
Nonetheless, information on previous
drug use should be carefully collected and
recorded for each patient and can be used
to stratify the results. This is particularly
important for long-acting antimalarial
drugs, such as SP and mefloquine.
4. STUDY POPULATION
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A more reliable approach to determining
previous drug use is to screen urine for
antimalarial drugs. While this may give a
more objective indication of current drug
Box 2: Use of measured elevation in body temperature vs. history of fever
The requirement to use only objectively measured elevations in body temperature (i.e. “measured
fever”) as opposed to allowing the use of a history of fever has been very controversial. The
following is a description of some of the concerns and issues involved with definitions of fever
and is intended to provide a rationale for current recommendations.
The greatest challenge to the use of a history of fever in this context is its unreliability, especially
among caregivers’ reports of fever in young children. Additionally, in many situations, a caregiver
will modify their response if they feel that the child will receive different treatment based on a
positive or negative report of fever. For example, if participation in a study such as this is generally
perceived as beneficial, the caregiver may misreport symptoms in an attempt to ensure the child’s
enrolment. Randomization in clinical trials reduces the chance for bias being introduced by the
study team; similarly, the use of objective measures of illness, whenever possible, reduces potential
bias introduced by subjective assessments made by either caregivers or study personnel.
Therefore, the global recommendation is that only objectively measured elevations in body
temperature should be used for both enrolment and post-treatment evaluations. This recommendation
does not imply that parasitaemic patients without manifest fever do not require treatment. It suggests
only that, for the purposes of this assessment, objective measures of fever are required for
enrolment. Patients not meeting this restrictive entry criterion still require treatment, albeit outside
the context of the assessment.
Modification of this recommendation on the basis of transmission intensity may be necessary in
some circumstances. In areas of low to moderate transmission, history of fever within the previous
24 hours can be used for enrolment and post-treatment evaluation. However, this modification
should be used only when insistence on requiring an objectively measured increase in body
temperature would cause great logistic and financial hardship due to difficulty in patient
recruitment and protracted enrolment periods. This modification should not be used if sufficient
numbers of patients with measured fever can be identified in a timely fashion.
The principal reason for allowing this flexibility in areas of low to moderate transmission and not
in areas of high transmission is the difference in prevailing programmatic response to in vivo test
results. In most areas of low to moderate transmission, the programmatic response to the presence
of parasitaemia after treatment does not differ between patients with or without overt clinical
symptoms (i.e. symptomatic and asymptomatic parasitaemia are weighted equally and require
rescue treatment as a treatment failure). This is not typically the case in areas of intense
transmission, where resolution of clinical symptoms is weighted more heavily in decision-making
than is persistence of parasitaemia without overt symptoms. Accurate reflection of clinical
indicators therefore becomes more important in areas of intense transmission.
use in the population, it is not a
mandatory component of this protocol.
A number of urine tests are described
in Annex 3.
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5.1 Overview
The study methods and procedures
are broken down into multiple activity
sections, including sample size
calculations, screening evaluation,
enrolment evaluation, informed consent
procedures, treatment, patient follow-up
evaluation, definition of study end-points,
and determination of study outcomes.
Additional sections will describe ethical
considerations, laboratory techniques,
data management, data analysis,
reporting, study and data quality
assurance, evaluation of study validity,
recommendations for determining the
level of malaria transmission intensity,
and recommendations for establishing
a sentinel site surveillance system for
treatment efficacy.
5.2 Sample size considerations
NOTE: The current recommendations
for appropriate methods of
calculating sample size represent
a substantial departure from the
most recent WHO protocol.
The previous protocol recommended
using the Lot Quality Assurance method
(LQAS), primarily as a way to minimize
the amount of fieldwork required.
Cumulative experience in the context
of in vivo assessments of antimalarial
drug efficacy has suggested substantial
methodological and analytical problems
with this method in practice.
Proper use of the LQAS method requires
patients to be randomly selected for
enrolment, which is rarely, if ever, done in
practice. Additionally, many programmes
used this statistical method as a
justification for enrolling small numbers
of patients and conducting very short
studies, but then dismissed or failed to
understand the statistical implications
inherent in this method (i.e. the study
was often analysed as if traditional
sample size calculations were done).
This led to many reports with incorrect
interpretation of study results.
The current recommendations therefore
call for the use of classical statistical
methods for determining sample size,
based on an expected proportion of
treatment failures, desired confidence
level (95%) and precision (5% or 10%).
While this method results in sample sizes
greater than would normally be the case
for LQAS, the sample sizes are still well
within the capacity of programmes. For
example, in the case of a test drug with
an expected failure rate lower than 15%,
a minimum of 50 patients should be
included in order to be representative
(see also Annex 4).
5.3 Screening evaluation
A rapid screening procedure should be
used in an outpatient setting to identify
patients who may meet enrolment
criteria. The exact procedures used,
the clinical and laboratory evaluations
performed, and the sequence in which
they are done during screening may vary
5. STUDY METHODS AND PROCEDURES
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from site to site. The typical screening
data set includes age, sex, temperature,
and body weight and height. If the local
situation, available resources, and capacity
of the outpatient unit permits, initial blood
slide examination and haemoglobin
concentration (or haematocrit1) can be
performed on all patients during the
screening procedure. Alternatively, these
tests can be limited to febrile patients.
If possible, a record book should be kept
in which all cases screened are entered,
with information on age, sex, address,
temperature, blood film, and, if applicable,
reason for exclusion from study. This
information can be very useful for data
interpretation and can provide clues about
the rate of transmission.
NOTE: At all times, patient health
and safety take precedence over
the study procedures. Patients
who are obviously severely ill
should be cared for immediately
as is appropriate for the facility.
A typical screening procedure involves
rapid identification of all potential patients
coming to the health facility (such as
those coming to a paediatric outpatient
clinic), measurement of temperature and
body weight and height, and recording
of basic demographic information
(name, age, sex). If a patient’s axillary
temperature exceeds or equals 37.5 °C,
blood should be collected for malaria
smear examination and measurement
of haemoglobin concentration. Patients
who do not meet these basic enrolment
criteria are treated by facility staff in
accordance with routine practice; however,
all clinical and laboratory findings obtained
during the screening procedure should
be shared with facility staff.
5.4 Initial clinical evaluation/
enrolment evaluation
All patients meeting the basic enrolment
criteria during the screening procedure
should be evaluated in greater depth by
clinical staff. Special care should be taken
to detect the presence or early signs of
febrile diseases other than malaria, as
these will probably necessitate exclusion
of the patient from the evaluation. Among
paediatric populations, the most frequent
confounding condition is lower respiratory
tract infections: cough or difficult breathing,
together with fast breathing, is an
indicator for identifying and excluding
patients suffering from such conditions.
Fast breathing is defined as a respiratory
frequency > 50/minute in infants under
12 months of age and > 40/minute
in children aged 12–59 months. Other
relatively common febrile conditions are
otitis media, tonsillitis, measles and
abscesses. Patients with these conditions
should not be enrolled, but obviously need
to be treated both for malaria (if they have
parasitaemia) and the other infection as
appropriate.
A case record form (Annex 5) should be
used to record the general information
and clinical observations for each patient1 Erythrocyte volume fraction.
15passed from screening into the study sentfrom screening. Particular care should be
taken to record detailed instructions on
how to find the patient’s home to ensure
that follow-up at home is possible should
the patient fail to return to the health
facility for scheduled visits.
5.5 Informed consent
Formal informed consent should be
obtained from all patients meeting the
enrolment criteria. The procedure for
obtaining consent should conform to
international and local guidelines for
research on human subjects (20). The
study should be fully explained to patients
or parents/guardians, including potential
benefits and risks. A recommended
format for an informed consent script
can be found in Annex 2.
5.6 Treatment
Patients meeting all enrolment criteria
should receive treatment only after
they have had the study fully explained
to them and have willingly provided
their informed consent. All antimalarial
treatment should be given by study team
members under observation using
established treatment regimens for the
drug under assessment. If more than
one treatment is being studied, patients
meeting all enrolment criteria should be
randomly assigned to their treatment arm.
Although this protocol is not intended
to be a comparative clinical trial, such
randomization is highly advisable.
Randomization is best achieved, and
more likely to avoid introduced bias, by
strictly following a computer-generated
randomization list, although other
methods (e.g. coin toss) have been used.
Annex 6 provides treatment schedules
for some antimalarial drugs of current
interest. Enrolled patients should be
observed for at least 30 minutes after
treatment to ensure that they do not
vomit the medicine. If vomiting occurs
within 30 minutes of treatment, the
full treatment dose should be repeated.
Ancillary treatments, such as antipyretics,
may be required and should be provided
to patients by the study team. Patients
with persistent vomiting (i.e. necessitating
more than a single repeat dose) should be
excluded from the study and immediately
referred to the health facility staff for
appropriate management.
Once the complete enrolment and
treatment procedure is finished, the
patient should be given a schedule
for routine follow-up visits. It is also
important to ensure that the patient (or
patient’s parent or guardian) knows that,
if symptoms return at any time during the
follow-up period, he or she should return
immediately to the assessment team for
re-evaluation, even if it is not a regularly
scheduled follow-up day.
5.7 Recommended duration of follow-up
The recommended duration of follow-up
is shorter for areas of intense malaria
transmission than for areas with low
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to moderate transmission. In both
situations, these are minimum
recommended follow-up periods –
programmes that are able to maintain
study quality over a longer period of
assessment, and have access to the
molecular techniques warranted by longer
follow-up periods, are encouraged to do
so. A detailed discussion of the principal
issues involved in selecting an appropriate
duration of follow-up for this protocol can
be found in Box 3.
Areas of intense transmission
The recommended minimum length of
follow-up is 14 days. Studies of longer
duration in areas of intense transmission
must be accompanied by molecular
assessment (polymerase chain reaction
(PCR)) to assist in distinguishing
recrudescence from reinfection. See
Annex 7 for sampling and storing filter
paper for molecular marker studies.
Areas of low to moderate transmission
The recommended length of follow-up
for assessments conducted in areas of low
to moderate transmission is 28 days.
However, in some circumstances,
assessments of shorter duration (14 days
minimum) can still provide useful results
and may be utilized. Molecular analysis
to assist in distinguishing recrudescence
from reinfection is highly recommended,
but not strictly essential, for studies of
more than 14 days’ duration conducted
in areas of low transmission.
The recommendations of this protocol reflect
an attempt to reconcile the benefits of extended
follow-up with the practical realities of
conducting that extended follow-up, espe-
cially in areas of intense malaria transmission.
These should be considered minimum
recommended follow-up periods; if pro-
grammes do in fact have the capacity to
conduct quality assessments with extended
follow-up, they are encouraged to do so.
5.8 Follow-up schedule
The basic follow-up schedule is presented
in table form in Annex 8. The day that
the patient is enrolled and receives the
first dose of medicine is traditionally
designated Day 0. Thereafter, the
schedule calls for clinical reassessments
to be made on Days 1, 2, 3 and 7,
then weekly for the remainder of the
follow-up period (i.e. on Day 14 for 14-day
assessments and Days 14, 21 and 28
for 28-day assessments). Patients should
always be advised to return on any day
during the follow-up period if symptoms
return and not to wait for scheduled visit
day. Although a minimum set of clinical
indicators for follow-up assessments
can be found in the example case record
form presented in Annex 5, clinical
reassessments should be sufficiently
thorough to ensure patient safety and
should include assessments not only
for potential treatment failure but also
for potential adverse reactions to the
treatment drug.
Blood films for parasite count should
be obtained and examined on Days 2,
3, 7 and 14 (and Days 21 and 28 if
appropriate) or on any other day if
the patient spontaneously returns.
17Box 3: Duration of post-treament follow-up
The length of time that is appropriate for assessment of treatment response in vivo has been a
topic of recent debate (21). Accumulated experience from a number of studies conducted in a
variety of settings has raised important observations and issues that are relevant to this debate.
• Studies with shorter follow-up (i.e. <14 days) will underestimate overall treatment failure rates.
This is especially true of drugs with longer elimination half-lives. The time to completely clear
a drug from the body is six times the elimination half-life (clearance = 6 x t
1/2
). Drug clearance
is the parameter that defines the length of the follow-up in the therapeutic efficacy test: for
SP, with an approximate sulfadoxine half-life of 100 hours (4 days), clearance will take 6 x 4 =
24 days; follow-up should therefore be for a minimum of 28 days, if possible.
• Follow-up periods longer than 14 days are appropriate for amodiaquine, chloroquine and SP
(28 days), for lumefantrine+artemether (42 days), and for mefloquine (63 days) to allow drug
levels in the blood to fall below the minimum therapeutic threshold. Any recrudescence of
parasites before this threshold is reached would be due to drug resistance; recrudescence
after this threshold is reached is not necessarily related to resistance (even sensitive parasites
could recrudesce if blood drug levels are subtherapeutic).
• The longer the duration of post-treatment follow-up, the greater the chance that reappearance
of parasites may be caused by reinfection rather than recrudescence. Inability to distinguish
between reinfection and recrudescence can lead either to an overestimated rate of failure (if
all reappearances are assumed to be recrudescences) or to an underestimated rate of failure
(if all reappearances are assumed to be reinfections). This risk increases with increasing
transmission intensity. More reinfections would be expected to occur between 14 and 28
days post-treatment in an area of intense transmission than in an area of very low transmission,
assuming no lingering prophylactic effect of the drug.
• Molecular techniques can help to distinguish recrudescence from reinfection. However,
these techniques are not definitive and they require specialized equipment and training that
exceed the typical capacity of the malaria control programme. Use of these tests becomes
essential when long-duration trials are conducted in areas of intense transmission. Without
them, any additional benefit gained from extending the duration of follow-up may be lost
as a result of inability to distinguish true treatment failure from reinfection.
• Longer-duration assessments have substantial logistic and cost implications that should not be
taken lightly. Even short-duration assessments are prone to invalidation due to high rates of
defaulting and loss to follow-up (see section 8). Extending the duration of follow-up requires
even greater effort to maintain an acceptably high rate of follow-up completion, as default rates
tend to increase with increasing follow-up periods. The additional costs of maintaining a study
team in the field for longer follow-up periods, of trying to locate defaulters in the community,
and of the molecular testing of samples all need to be weighed against the value of the
additional information to the decision-making process of the programme.
• The intended purpose of this protocol is to collect data in support of programmatic decision-
making as opposed to conducting research on drug resistance per se. While it may not be
an ideal situation, experience has shown that few countries have changed first-line malaria
treatment policy at a very early stage in the development of antimalarial drug resistance.
Therefore, the added benefit of information gained from extended follow-up must also
be weighed against the programme’s ability to act on that information.
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Additionally, blood films should be
obtained whenever parasitological
reassessment is requested by the clinical
staff for reasons of patient safety. Study
patients should be closely monitored in
order to minimize risk. Haemoglobin
status is typically reassessed on Day 14
(and Day 28, if appropriate). Because
many drugs require multiple day dosing,
the initial visits are critical not only for the
efficacy assessment but also for patient
safety; defaulters at this stage will not
have received a complete course of
treatment and may be at risk. The
ultimate success of the study rests
on minimizing loss to follow-up.
While patients can be encouraged
to return on their own for scheduled
follow-up visits, it is essential that
provisions be made ahead of time for
locating patients at home if they do
not attend as requested. This requires
obtaining very detailed directions to the
home during enrolment and study team
members familiar with the community
who can be responsible for home visits.
The schedule for treatment and follow-up
examination given in this protocol must
be followed rigorously to ensure data
integrity. Patients who fail to appear on
Day 1 and Day 2 and miss one dose of
the treatment are withdrawn from the
study definitively. After Day 3, patients
who fail to appear on Day 7 but present
on Day 8 (likewise Days 14/15, Days 21/
22, and Days 28/29) may still be included
in the study group. Deviation from the
protocol of more than 1 day cannot be
allowed, both for the safety of the patient
and for the relevance of the data.
NOTE: Box 2 discusses the use of
objectively measured elevations
in body temperature and the
appropriate situations in which
history of fever could be used.
The same fever indicator should
be used throughout the assessment.
For example, assessments requiring a
measured fever for enrolment should
also require a measured fever for
determining whether to collect additional
blood smears and for identifying potential
treatment failures during follow-up
(see section on definitions of response
to treatment). Assessments conducted
in areas that have chosen to accept the
use of a history of fever during the
preceding 24 hours for enrolment,
should also use history of fever in
the preceding 24 hours to determine
when to take additional blood films and
for identification of potential treatment
failure. Assessments should not use
one fever criterion for enrolment and
a different fever criterion for follow-up
assessment.
There is one important exception to
the above statements. In the definition
of early treatment failure, there is an
absolute requirement for a measured
fever on Day 3 in order to classify the
response as a failure, even if history
of fever is used elsewhere. The reason
for this is that fever on Day 2 is a frequent
occurrence and use of history of fever
in the preceding 24 hours on Day 3
would overestimate early treatment failure.
195.9 Rescue treatment
NOTE: Indications for provision of rescue
treatment during a therapeutic
efficacy test will be different for
assessments conducted in areas
of low to moderate transmission
from those conducted in areas of intense
transmission.
These differences reflect differences in
programmatic priorities within different
regions. Traditionally, because underlying
acquired immunity among individuals
with lifetime exposure to intense malaria
transmission allows for parasitological
failures to occur without concurrent
clinical failure, studies done in these areas
typically do not provide rescue treatment
for asymptomatic parasitological failures;
rescue treatment is given only to clinical
failures. The exception is at the end of
the follow-up period, when all patients
with parasites are given rescue treatment
regardless of clinical status. In contrast,
programmes in areas of low to moderate
malaria transmission typically do not
distinguish between parasitological
failures and clinical failures (which,
because of low levels of immunity,
frequently occur together anyway),
and studies done in these areas will
therefore provide rescue treatment
for both asymptomatic parasitological
failures or clinical failures.
If an assessment is being conducted in an
area of intense transmission and patients
with asymptomatic parasitaemia are not
being given rescue treatment, it is
important for these patients to be monitored
closely. This may entail asking a patient
to return the next day, even if this is not
a regularly scheduled follow-up day, or
even admitting the patient for observation.
At any time, a patient who is deemed
unfit to continue the assessment because
of safety concerns may be withdrawn
from the assessment and classified in the
failure group. If a patient is parasitaemic
at a time when monitoring must cease,
rescue treatment is recommended to
minimize the risk of symptomatic disease
emerging in a patient who was enrolled
in the study.
“Rescue treatment” is defined as a
second-line treatment that is given to
a study patient when a treatment failure
has been identified (see note above).
The choice of this treatment depends
on the drug under assessment: ideally,
the rescue treatment would use a drug
that has an established efficacy and safety
record in the case of infections resistant
to the treatment under assessment and
that may or may not be the officially
recommended second-line malaria
treatment in the country in question.
Patients experiencing severe deterioration
in clinical status during the study should
be referred immediately for appropriate
inpatient care. However, most study patients
should not develop severe illness — in fact,
the study design aims to provide sufficiently
close patient monitoring to allow for
intervention before severe illness can
develop.
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5.10 Definition of study end-points
A study end-point is the point at which
a patient will no longer be followed up
within the context of the assessment.
Valid study end-points include treatment
failure, completion of the follow-up period
without treatment failure, loss to follow-
up, withdrawal from study (voluntary
and involuntary), and protocol violation.
• Treatment failure and completion
of study without treatment failure.
For the purposes of this study, treatment
classification occurs when an enrolled
patient meets the criteria defining one of
three possible categories of treatment
failure or the criteria for treatment
success. These are described in detail in
section 5.11.
• Loss to follow-up. Loss to follow-up
occurs when, despite all reasonable
efforts, an enrolled patient cannot be
found. Examples include failure to find
a patient in the community after he
or she misses a scheduled follow-up visit
or moves out of the study area. Loss to
follow-up differs from voluntary withdrawal:
voluntary withdrawal suggests a conscious
decision to no longer participate in the
study, whereas loss to follow-up may
have nothing at all to do with a specific
decision by the patient to participate or
not. Moreover, it may still be possible to
ascertain the health status of a person
who withdraws from the study, whereas
the health status of a patient lost to
follow-up is always uncertain.
• Withdrawal from study. One of the
basic requirements for ethical treatment
of human subjects is that they are always
free to end their participation in the study
at any time. A study patient (or a study
patient’s parent or guardian) who decides
not to participate any further in the study
is referred to as a voluntary withdrawal.
An example of a cause for involuntary
withdrawal would development of a
concomitant illness that would interfere
with the clear interpretation of study
outcomes. It is recommended that
reinfections identified by PCR be classified
as withdrawals rather than as treatment
successes. The rationale for this is
presented in Box 4.
• Protocol violation. A protocol violation
occurs when a study patient is removed
from the study because of an event that
does not allow for continued accurate
interpretation of response to treatment.
Examples include missed treatment dose,
detection of a mixed infection during
follow-up, or a credible report of additional
antimalarial drug use outside the study
protocol (such as self-medication).
In all cases, reasons for loss to follow-up,
withdrawal, and protocol violation should
be recorded and reported in detail. (See
also section 7 below on data analysis
and interpretation regarding the handling
of loss to follow-up, withdrawals, and
protocol violations during analysis.)
21Box 4: Classification of reinfections identified by PCR
It is recommended that studies that include patient follow-up periods longer than 14 days use
molecular techniques to differentiate recrudescences from reinfections. While most of these
infections may, in fact, be reinfections, there are two issues that make their appropriate
classification problematic. First, the usual PCR techniques used for this purpose are
insufficiently sensitive to pick up minority populations of parasites present at Day 0. It is
therefore possible that “new” parasites identified during follow-up actually represent recrudescence
of parasites from a resistant minority population that was present from the start rather than
true reinfections. Second, once a reappearance of parasites has been identified, the patient
would receive rescue treatment (in areas of high transmission, this would occur only when in
combination with fever; in areas of low to moderate transmission, it would occur regardless of
presence of fever). Provision of additional treatment at this point would make further interpretation
of follow-up for that patient impossible and potentially “mask” a true treatment failure. In other
words, there is a possibility, albeit relatively small, that a recrudescence might have occurred
at a later point during follow-up in a patient experiencing, and being treated for, a reinfection.
In either case, classification of all of these reinfections as treatment successes would lead to
underestimation of true failure rates. Classifying all reinfections as treatment failures would
lead to overestimation of true failure rates (and would render PCR unnecessary). For consistency,
it is recommended that reinfections (as well as PCR unclassifiable results) be classified as
involuntary withdrawals, as would be the case if the patient had self-treated during follow-up:
the implications for bias are essentially the same in both circumstances.
NOTE: The classification system for
response to treatment has been
changed in this protocol. These
changes are aimed primarily at
reconciling differences between
the previous protocol as it was applied
in areas of intense transmission with
that used in areas of low to moderate
transmission. Additionally, under the
previous classification system used in areas
of intense transmission, asymptomatic
parasitological failures were not
specifically identified and reported. These
changes allow for more comprehensive
reporting of treatment failure.
5.11 Determination of study outcomes
The classification system of response to
treatment has been modified (see Annex 9)
and now has three categories for treatment
failure (Early Treatment Failure, Late
Clinical Failure, and Late Parasitological
Failure) and one for treatment success
(Adequate Clinical and Parasitological
Response). People familiar with the
previous classification system should
review the new category definitions
carefully, as some subtle but critical
changes have been introduced. A
description of these changes follows.
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• Early Treatment Failure. There is now
only a single uniform definition for Early
Treatment Failure regardless of intensity
of transmission; it has been modified to
reflect an absolute requirement for a blood
smear to be obtained on Day 2. Previously,
in areas of intense transmission, a blood
slide taken on Day 2 was required only if
fever was present. This change has been
made for reasons of study patient safety:
waiting until Day 3 to obtain the first
follow-up post-treatment blood smear was
felt to be too long and risked delays in
provision of rescue treatment for patients
with unresponsive parasitaemia. There
is also an absolute requirement for a
measured increase in temperature on
Day 3 in the presence of parasitaemia
for a response to be classified as an Early
Treatment Failure (history of fever on
Day 3 in the presence of parasitaemia
is not an acceptable indicator of failure).
• Late Clinical Failure. There is a single
definition of Late Clinical Failure
regardless of transmission intensity.
However, minor variations exist because
of differences in recommended duration
of follow-up (14 days for intense
transmission areas, 28 days for low
to moderate transmission areas).
Additionally, in areas of low to moderate
transmission and under certain
circumstances, use of history of fever
in the preceding 24 hours, instead of
a measured fever, is allowable when
necessary (see Box 2).
• Late Parasitological Failure. Although
there is a single definition of Late
Parasitological Failure, differences exist
between transmission areas for the same
reasons as stated above. Additionally,
this is a new category for people familiar
with using the previous protocol in areas
of intense transmission. Previously,
asymptomatic parasitaemia occurring
after Day 4 was included in the category
of Adequate Clinical Response.
However, information on the frequency
of parasitological failures is important to
understanding drug efficacy and should
not be lost.
• Adequate Clinical and Parasitological
Response. The definition of an adequate
response to treatment also differed by
transmission intensity in the previous
protocol. The new definition of an
adequate response to therapy reconciles
these differences and is applied only to
those responses that demonstrate both
clinical and parasitological resolution by
the end of the follow-up period.
23Therapeutic efficacy tests should alwaysbe conducted under the direct supervision
of qualified medical personnel. At all
times, the safety and welfare of the
individual patient should be ensured
to the greatest extent possible, and
appropriate management of each
patient should take priority over the
conduct of the test.
While this protocol is intended primarily
as a programmatic tool, the study still
should be conducted as if it were a
research study. In almost all conceivable
situations, this would require independent
ethical review of the protocol (especially
when the drug under study is not
currently a recommended malaria
6. ETHICAL CONSIDERATIONS
treatment in the country in question).
Patients under consideration for
enrolment should have both the risks
and benefits of the study explained
thoroughly through a formal informed
consent process and their participation
should not be coerced in any fashion.
The investigators must establish secure
safeguards of the confidentiality of
subjects’ data.
Additionally, all test procedures should
be conducted with the patient’s health
and welfare given priority over continuing
in the assessment. Patients have the right
to withdraw from the study at any time
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7.1 Data management
Annex 5 provides examples of data
collection forms. As mentioned
previously, the data on these forms
should be considered as the minimum
essential variables to consider: individual
programmes may want to collect
additional information that is relevant
to their particular situation.
The primary study coordinator should
thoroughly check all data forms on a daily
basis, not only for completeness but also
to ensure that they are being filled out
clearly, that the information collected
makes sense, and, most importantly,
that study patients are classified correctly
and that those who qualify for rescue
treatment have received that treatment.
Care should also be taken to ensure
that samples are correctly labelled and
that all laboratory results are reported
correctly and promptly.
Use of a computer greatly simplifies
data cleaning and analysis, although
the process can be done “by hand”.
If computer-based data entry is used,
double-entry validation is strongly
recommended to minimize clerical errors
in transcription. Double-entry validation
is typically done by having two different
data entry clerks enter the same
information into two separate files,
and then comparing the two files.
Any differences between the files
suggest mistakes in data entry that
can be corrected by referring to the
original hard-copy data forms.
7. DATA MANAGEMENT AND ANALYSIS
7.2 Data analysis
NOTE: The recommended method for
data analysis represents a major
change from the previous protocol.
The recommended method for analysis
of data obtained from this protocol is
survival analysis. Computer programmes
are available for this method of analysis
(for example, EpiInfo 2002, available
free via: www.cdc.gov, or Excel data
analysis sheets, available free via:
www.rbm.who.int), but calculation
by hand is not difficult (see Annex 10).
The benefits of this method of analysis
include the use of data from patients who
have withdrawn or are lost during follow-up,
easy calculation of mean time to failure,
and calculation of a reasonably unbiased
estimate of failure rates.
To obtain results that can be compared
with historical results, it is also
recommended that data be analysed
using the traditional “per-protocol”
approach. This approach retains for
analysis only data from patients with
evaluable results, i.e. those patients with
known efficacy end-points, such as Early
Treatment Failure, Late Clinical Failure,
Late Parasitological Failure, and Adequate
Clinical and Parasitological Response;
data from all other patients are excluded
from analysis and do not contribute to the
denominator. Nonetheless, if this method
is used, the number of patients excluded
25from analysis — as well as the reasons fortheir exclusion — should be reported fully.
Intent-to-treat (ITT) analysis has also
been used. In ITT analysis, all patients
randomly allocated to a treatment group
are retained in analysis whether or not
there is an evaluable outcome; that is,
they contribute to the denominator if not
the numerator. The primary purpose of
ITT analysis is to maintain the integrity
of the randomization process, which is
important for randomized, comparative
clinical trials; this protocol, however, is not
intended primarily for comparative trials.
7.3 Use of the data for updating
treatment policy
The appropriate interpretation of data
derived from this protocol has generated
considerable debate, and revolves around
the simple question of how much treatment
failure is too much to justify further use of
the drug in question. While it is tempting
to define a threshold of failure with a
single number above which treatment
failure is unacceptable, in practice there
is no simple answer to this question —
the answer will depend on many factors
unique to each situation. For example,
the tolerance for treatment failure will
increase if the potential alternatives are
not readily available to the programme,
are too costly for programmatic use,
or are associated with serious safety
concerns. Programmes in areas of intense
transmission have historically had fairly
high tolerance for treatment failure,
reflected by the fact that relatively few
countries in sub-Saharan Africa have
changed treatment policy despite
reportedly high levels of chloroquine
treatment failure. Furthermore,
programmes in areas of intense
transmission have traditionally excluded
asymptomatic parasitological failure
from consideration, and have reacted
programmatically only to clinical failure
rates (as reflected in the design and
interpretation of the 1996 WHO
standardized in vivo protocol for areas
of intense transmission). The rationale
behind this approach is related to the
effects of acquired immunity and
the frequency with which apparently
asymptomatic parasitaemia occurs.
As more information accumulates
regarding the health effects (especially
the haematological effects) of apparently
asymptomatic parasitaemia, as use of
effective preventive interventions (such
as insecticide-treated nets) becomes more
widespread, and as financial mechanisms
evolve to make treatments with high
parasitological efficacy programmatically
viable, this approach is likely to change.
Conversely, programmes in areas of low
transmission have historically had a very
low tolerance for any failure and have
treated parasitological failure and clinical
failure equally (aided, no doubt, by the
relative lack of acquired immunity and
the generally strong correlation between
parasitological and clinical failure).
There have been attempts to define such
cut-offs, most concerning a transition
from chloroquine to SP (22–24). WHO
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has simplified these earlier attempts into
very programmatic terms, which provide a
good “rule of thumb” for initiating debate
on malaria treatment policy in a given
country (25). In this scheme (developed
primarily for areas of intense transmission),
four periods leading to drug policy change
are defined: “Grace Period” when clinical
failure rates are between 0% and 4%;
“Alert” when they are between 5% and
14%; “Action” when they are between
15% and 24%; and finally “Change”
when they are 25% and above. Because
of the lead time needed to actually
change treatment policy (periods often
between 12 to 18 months and as long as
10 years have been recorded), the process
of change must be started before high
levels of treatment failure are reached.
Finally, it should also be noted that many
factors influence the development of
malaria treatment policy, of which in vivo
efficacy is but one. By their very nature,
in vivo studies reflect the use of malaria
drugs under optimal conditions, i.e.
correct diagnosis followed by appropriate
dosing with drugs of known high quality
given under direct observation, thereby
ensuring compliance. Use in practice
may be vastly different, so that a
highly efficacious drug may have poor
programmatic effectiveness. Providers’
treatment practices, patients’ compliance
with recommended drug doses and
schedules, drug availability, adverse
effects (even minor side-effects), safety
in high-risk groups such as infants
and pregnant women, and cost are
all important factors in determining the
best choice of drug for malaria treatment
within a programmatic context.
NOTE: During the WHO consultation
on the Goal of Antimalarial
Treatment Policy in the WHO
Africa Region held in Harare,
Zimbabwe, 14–15 August 2003,
the experts reached the consensus that
persistent parasitaemia is associated with
increased risk of clinical episode, anemia,
and increased gametocyte carriage.
Therefore, the experts agreed that
parasitological response should be an
additional indicator for the interpretation of
the therapeutic efficacy test. The cut-off
point for policy change using the standard
WHO protocol for high transmission area
is now as follows: Adequate Clinical and
Parasitological Response < 75% (Total
Failure ≥ 25%) and Adequate Clinical
Response < 85% (Clinical Failure ≥ 15%).
The definition of Adequate Clinical
Response remains the same as in 1996.
Using the new classification, it is equal
to the sum of Adequate Clinical and
Parasitological Response and Late
Parasitological Failure.
Total Failure is equal to the sum of Early
Treatment Failure, Late Clinical Failure
and Late Parasitological Failure.
Clinical Failure is equal to the sum of
Early Treatment Failure and Late Clinical
Failure.
277.4 Reporting
Proper reporting of results, whether
for programmatic use or for publication,
is of paramount importance. In order
to maximize the usefulness of studies
and their comparability between sites
and over time, adherence to the details
of this protocol is critical. Interpretation,
and subsequent comparability, of the
results of past in vivo studies has suffered
from innumerable protocol modifications.
In one extreme example, in vivo studies
done in the same general location during
the same time frame yielded substantially
different results, principally due to
modifications to the “standardized”
protocol introduced by individual
investigators. Situations such as this
have led to confusion and, worse,
dismissal and disregard of results
by decision-makers.
Essential to the proper interpretation
of results is complete and proper reporting
of both methods used and results. Despite
efforts to standardize these methods,
differences will remain between studies
conducted in areas of intense transmission
and those conducted in areas of low
to moderate transmission. Similarly,
the exact method of analysis should be
reported (for example, whether results
reflect survival analysis, per-protocol,
or intent-to-treat). Deviations from
this protocol are strongly discouraged;
however, if any deviation is included,
its exact nature and the rationale behind
it must be clearly stated.
Formal reporting should also include
results of data quality assurance,
especially of blood smear examination,
using the methods described in section 8.
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8.1 Temperatures
Because outcome classifications
are dependent on measured body
temperatures (especially in areas of
high transmission), both thermometers
and the temperature-taking technique
of the clinical staff should be reviewed.
The quality of temperature-taking
technique should be ensured through
proper training and continuing
supervision. Any measured temperature
below 36.0 °C should be repeated.
Before the assessment, thermometers
should be tested in a water-bath of
known temperature (i.e. measured
using a reliable thermometer, preferably
of laboratory quality, before the study
thermometers are tested). If logistically
possible, this procedure should be
repeated during and at the end
of the assessment.
8.2 Body weights
Because dosing is based on body weight,
it is important to ensure the reliability of
the scales used in the study. The accuracy
of scales should be verified before use and
at least once during the study.
8.3 Blood slides
8.3.1 Reagent preparation
Details of reagent preparation can be
found in Annex 11.
8. TECHNICAL CONSIDERATIONS
 AND QUALITY ASSURANCE
8.3.2 Slide preparation and staining
Preparation and staining of blood slides
follows the procedure outlined in Basic
malaria microscopy, Part 1 (26). Fresh
Giemsa stain dilution should be prepared
at least once each day and possibly more
often, depending on the number of slides
being processed. The best results are
obtained by staining slides for 45–60
minutes in a 2.5–3% Giemsa stain
solution. Increasing the concentration
of the Giemsa solution can reduce the
time needed for staining, but the stain
quality (and therefore the quality of the
microscopical examination) will be less
predictable.
In general, it is best to take two blood
slides per patient. One slide can then be
rapidly stained (10% Giemsa for 10–15
minutes) for initial screening of patients,
while the other is retained. Should the
patient subsequently be enrolled, the
second slide can be stained more carefully
(e.g. 2.5–3% Giemsa for 45–60 minutes).
This slower staining method should also
be used for all slides obtained during
patient follow-up visits. The use of slides
with one frosted edge that can be marked
or of conventional slides marked with a
“permanent” glass writing pen is
recommended.
8.3.3 Examination and interpretation
• Screening smears. The thick blood
smear for initial screening should be
examined by counting the asexual
parasites and the white blood cells in
a limited number of microscopic fields.
Adequate parasitaemia for enrolment
requires at least 1 parasite for every
293–4 white blood cells, corresponding toapproximately 2000 asexual parasites/µl,
for high transmission areas, and at least
1 parasite for every 6–8 white blood cells,
corresponding to approximately 1000
asexual parasites/µl, for low to moderate
transmission areas.
• Enrolment and follow-up smears.
The second blood smear should be
used to calculate the parasite density of
enrolled patients. Blood smears taken
during patient follow-up should be
examined in the same manner.
Parasite density is calculated by counting
the number of asexual parasites against
a set number of white blood cells (WBCs)
— typically 200 or 300 — in the thick
blood film, using a hand tally counter.
Once a field has been started, it should
always be counted to completion; the final
WBC count will therefore rarely be exactly
200. If more than 500 parasites have been
counted before 200 WBCs have been
reached, the count is stopped after the
reading of the last field has been completed.
Parasite density, expressed as the number
of asexual parasites per microlitre (µl),
is calculated by dividing the number
of asexual parasites by the number
of WBCs counted and then multiplying
by an assumed WBC density (typically
6000–8000 WBCs/µl).
The same technique should be employed
for establishing parasite counts on each of
the subsequent blood film examinations.
Parasitaemia is measured by counting
the number of asexual parasites against
a number of WBCs in the thick blood film.
When the number of asexual parasites
drops below 10 per 200 WBCs, counting
should be done against at least 500
WBCs (i.e. to the completion of the field
in which the 500th WBC is counted).
A blood slide can be considered negative
when the examination of 100 thick-film
fields does not show the presence of
asexual parasites. The presence of
gametocytes on any enrolment or
follow-up slide should be noted, but this
information does not contribute to the
basic evaluation of the test.
In addition, 100 fields of the second thick
film should be examined to exclude mixed
infections; in case of any doubt, the thin
film should be examined for confirmation.
If examination of the thin film is not
conclusive, the patient should be excluded
from the study after complete treatment.
8.3.4 Quality control
Quality control of microscopy involves
ensuring that good-quality Giemsa stain
is used, that staining procedures adhere
to recognized methods, that microscopes
are of adequate quality and in good repair,
and that the microscopy results are reliable.
• Quality control for Giemsa stain
To ensure that proper staining results
have been achieved, a known positive
smear should be included with each new
batch of working Giemsa stain. Control
slides may be prepared from a patient’s
blood and stored for future use.
Method. From a patient known to have
malaria infection, collect a blood sample in
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an EDTA (ethylenediaminetetraacetic acid)
blood tube. An ideal blood sample has at
least one parasite in every 2–3 fields on
a thin blood smear. Make as many thin
smears as possible, preferably within one
hour of drawing the blood from the patient.
Allow the smears to dry quickly, using a
fan or blower at room temperature. Fix the
smears in absolute (100%) methanol and
allow them to dry. Place them, touching
back to back, in a box with separating
grooves. Label the outside of the box with
the species, date and “Giemsa control
slides”. The slides can be stored at room
temperature but will last longer if stored
at or below –70 °C. Just before use,
remove the slide from the box and allow
the condensation to evaporate; label the
slide with the date and “+ control”. The
smear can then be stained and examined
to check that the working solution of
Giemsa stain is of good quality.
• Quality control for microscopic
examination and quantification
The procedure for assessing microscopy
results should emphasize the reproducibility
of final outcome classifications over
reproducibility of exact parasite counts:
even two highly experienced microscopists
can differ widely in their parasite counts,
especially at higher parasite densities.
For the purposes of this assessment,
discrepant results that lead to a change in
outcome classification for a given patient
are more important than discrepant results
for individual blood slides that make no
difference to the ultimate classification.
Method. Ideally, two qualified microscopists
should independently read all of the slides
and parasite densities will be calculated by
averaging the two counts. Blood smears
with non-concordant results (differences
between the two microscopists in species
diagnosis, or differences in parasite density
of > 50%) will be re-examined by a third,
independent microscopist, and parasite
density will be calculated by averaging the
two most concordant counts.
If this is not feasible, a random selection
of 10% of the enrolled patients or a
minimum of 10 randomly selected
patients, whichever is the greater, should
be selected for rechecking. The second
microscopist should be blinded to the
patient number, day of follow-up, original
results, and outcome. The second
microscopist should re-examine all
microscope slides from patients selected
for quality control and should provide
results as if reading the slide for the first
time (i.e. determine whether negative or
positive and, if positive, provide a parasite
count using standard procedures).
After all slides have been reviewed,
the new patient-specific data should
be reassembled and the results should
be used to assign an outcome using
the recommended classification system.
The new outcome should be compared
with the original and discrepancies noted.
If more than 10% of the subsample (i.e.
1 patient for a subsample of 10 patients)
has non concordant outcomes, all study
results should be reviewed.
318.4 Haematological assessment
Haematological assessment of the patient
should be done whenever possible by
measuring either the haematocrit or the
haemoglobin concentration. Measuring
haematocrit requires specialized equipment
and supplies (such as a centrifuge and
microhaematocrit capillary tubes);
haemoglobin concentration is most easily
measured by using commercially available,
portable photospectrometers, but fairly simple
laboratory-based assays are also available.
Valid comparisons between
Day 0 and Day 14 require either haematocrit
values or quantitatively determined
haemoglobin levels; semi-quantitative
methods, such as the WHO haemoglobin
colour scale, are not accurate enough
for use in these studies.
In healthy persons, the haematocrit
(expressed as a percentage) is roughly
3 times the haemoglobin concentration
(expressed in grams per decilitre). This
ratio is maintained in normocytic anaemia,
but in most of the tropical forms of chronic
anaemia the ratio is 3.3:1. Enrolment
requires a haemoglobin level above 5.0 g/dl
or a haematocrit above 15%.
8.5 Drug quality
The drugs used in a therapeutic efficacy
test must be of unquestionable quality.
Unfortunately, experience suggests
that merely buying test drugs from an
otherwise reputable source is insufficient
to guarantee quality, as poorly manufactured
antimalarial drugs have been identified
from many sources.
To the extent possible, programmes
should obtain test drugs from WHO or
other internationally recognized sources
of good-quality drugs. For drugs that
cannot be obtained through such sources,
it is recommended that the drugs used
in a therapeutic efficacy test be tested
(for both content and dissolution) by
a qualified pharmaceutical laboratory
before studies begin.
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The validity of a study may be compromised
by exclusion of a high proportion of
enrolled patients from analysis, by too-
frequent protocol violations, or by frequent
clinical or laboratory mistakes leading to
misclassification of outcomes. A primary
responsibility of the study coordinator
is to maintain vigilance over the quality
of all aspects of data collection and study
conduct. Mistakes must be identified
and corrected rapidly to minimize wasted
effort or invalidation of the study results.
In general, if 20% or more of enrolled
patients are lost to follow-up or are
otherwise excluded due to protocol violations,
study validity can be questionable. This is
especially true if a high rate of loss to
follow-up or exclusion also reduces the
sample size to less than the calculated
minimum. While the latter problem can
be dealt with by enrolling more patients
than needed to account for expected
drop-out, the former frequently requires
tracking patients into the community
if they fail to return for follow-up visits,
plus constant efforts to ensure the quality
of data collection.
It is recommended that misclassification
of outcomes be kept below 10% of total
sample size. Clinical mistakes can be
avoided only by adequate training of
clinical staff before the study begins and
constant supervision during the study.
Laboratory mistakes should be avoided
by staffing the laboratory with experienced
and qualified technicians and by following
the quality assurance methods described
above.
A frequent cause of misclassification of
outcomes is poor microscopy — especially
inaccurate counting of asexual parasites
and subsequent miscalculation of parasite
density. Critical mistakes in basic microscopy
include misdiagnosis of parasite species
and missing mixed infections at enrolment.
Accurate parasite counts are critical
throughout the study: inaccurate counts
on Day 0 can lead to an increase in
protocol violations (e.g. enrolling patients
with too few parasites) or loss of enrolment
efficiency (e.g. excluding patients with
adequate numbers of parasites).
Misclassification of outcomes can occur
when parasite counts are inaccurate
on Day 0 and/or Day 3 (when absolute
numbers of parasites need to be
compared to determine whether ≥ 25%
of the Day 0 count remains on Day 3)
or during follow-up.
After quality assurance of blood slides
using the methods described above, all
patient outcomes should be reclassified
using the corrected blood slide results.
If 10% of patients or more have changes
in outcome classifications, the study
should be considered invalid.
9. EVALUATING STUDY VALIDITY
33The development of clinical immunitydepends largely on the frequency of
parasite exposure from birth. In areas of
stable high-intensity transmission, clinical
immunity is acquired early in life, often
well before the child’s fifth birthday. As the
intensity of transmission declines to very
low levels and becomes unstable, clinical
disease events may be equally common
among young children, older children,
and adults as populations fail to develop
an effective clinical immunity. Under these
conditions, the overall frequency of disease,
in an average year, is generally low.
In much of sub-Saharan Africa there is
intense transmission of P. falciparum,
clinical immunity is acquired early in life,
and the greatest concentration of disease
burden falls upon infants and young
children. However, the climatic and
ecological conditions in some areas of
the continent do support exceptionally
low-intensity transmission, with a tendency
towards periodic epidemics; these areas
are typically at high altitude, in arid areas
or urban settings.
For the practical purposes of drug-
sensitivity testing, it is important to
distinguish areas with conditions that result
in a slow acquisition of clinical immunity
(low to moderate transmission areas)
from those where there is relatively rapid
acquisition of immunity (high transmission
areas). In areas of low to moderate
transmission, recruitment of patients
for drug-sensitivity testing should reflect
the local disease ecology and cover both
children and adults (although, even here,
children under 5 years of age may be at
greater risk for other reasons and would
ideally still be a focus of study). In areas of
high transmission, sensitivity testing would
focus on children aged less than 5 years.
Typically, areas of low-intensity P. falciparum
transmission would be those that fall
between the classical definitions of
unstable malaria and stable hypoendemicity.
There are a number of ways in which
these epidemiological definitions can be
described, involving complex parameter
estimation through entomological studies
(27). These approaches are often beyond
the scope of the teams investigating drug
sensitivity. For practical purposes,
investigators should aim to distinguish
unstable malaria settings as follows:
• Consulting existing data. A database
containing the results of extensive
parasitological and entomological surveys
undertaken across the continent has been
created by the Mapping Malaria Risk in
Africa (MARA) collaboration. Searches can
be made of these data at: www.mara.org.za.
All areas where the prevalence of infection
among children aged under 10 years is
10% or less can be regarded as hypoendemic,
low intensity or potentially unstable.
In addition, MARA has developed a series
of maps of modelled malaria risk that can
be viewed at the same web site. The
country maps identify geographical areas
that, according to climatic determinants,
are unlikely to support stable endemicity.
In general terms, areas with a fuzzy logic
value of less than 0.25 (see the web site
for details on fuzzy logic modelling) are
unlikely to support stable, endemic malaria
and can be regarded as potentially unstable
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(28). The climate models do not provide
adequate predictions of urban malaria
transmission, as these are often lower
in reality than is suggested by the models.
Other national databases should also
be consulted; for Kenya, for example,
a national archive can be found at:
www.kmis.org.
• Empirical estimation of malaria
infection risks. The simplest and most
frequently performed surveys of malaria
endemicity are cross-sectional infection
prevalence surveys. Depending upon
resources, these surveys can be undertaken
among randomly selected children (aged
2–9 years) resident in the community
surrounding the clinic, or among infants
(aged 3–11 months) attending the clinic
for routine vaccination or growth monitoring.
The latter will provide a lower estimate
of the infection prevalence compared
with older children but, conversely,
might overestimate infection risks if the
attendance is associated with illness.
To identify areas of 10% prevalence of
infection, a sample size of 200 children
would allow a 95% confidence interval
of 6–14%. Thick and thin blood smears
would have to be taken from finger-prick
samples following informed consent from
the parents or normal guardians of the
children. Slides would be examined as
described elsewhere in this protocol.
Spleen rate has also been used as a proxy
marker of malaria endemicity. Definition of
hypoendemic, mesoendemic, hyperendemic
and holoendemic malaria in relation to the
spleen rate and the parasite rate are given
in Annex 12. However, these markers
cannot be taken as a reliable index since
the spleen and parasites rates are arbitrary
and do not capture the seasonal nature
of transmission (27).
• Age distribution of clinical cases.
A proximate measure of transmission
stability could be derived directly from an
examination of the clinical case data at
the clinic. By summing the number of
adult malaria cases (aged ≥ 15 years) and
the number of cases aged < 15 years over
an entire year or transmission season, the
adult : child case ratio can be calculated.
A ratio of 1 or greater, i.e. equivalent or
greater numbers of adult cases compared
with children, would suggest a slow
development of clinical immunity in the
community and hence low-intensity
transmission. This clinical description
makes a number of assumptions:
– the community using the clinic is typical
of many rural populations in developing
countries, with approximately half of the
population aged < 15 years;
– there are no age-dependent biases in
clinic attendance; and
– clinical diagnosis is of a high standard
and includes microscopy.
The last assumption is important because
many clinic records pertain to presumptive
malaria diagnoses, which may be completely
different from true, parasitologically confirmed
clinical cases. Where investigators feel that
the case definitions are inappropriate for
retrospective review, they can mount a
limited prospective assessment of clinical
malaria among children and adults with
improved diagnostics.
35The overriding purpose of this protocol
is to provide evidence to inform the
development of guidelines and/or policies
for the treatment of uncomplicated malaria.
In practice, most countries have developed
and implemented a single, uniform policy
for the entire country. In a few countries,
treatment guidelines are more closely
tailored to the local situation, with two
or more different policies for different
geographical regions of the country.
In either case, it is necessary to have
reliable and current efficacy data.
Ideally, antimalarial drug treatment policy
and/or guidelines should be developed,
reviewed regularly, and updated as needed,
on the basis of current evidence obtained
from studies using this standardized
protocol. As far as possible, treatment
guidelines should also reflect local
resistance patterns to ensure that
efficacious treatment will be provided
to the greatest possible proportion
of the population.
To accomplish the dual goals of timely
and ongoing data collection and local
relevance, a sentinel site surveillance
system for antimalarial drug efficacy
should be established. Although no
definitive scientific advice can be given
regarding the number of sites needed,
experience suggests that a balance
between representativeness and
practicality can be achieved with four
to eight sites. Programmes should
increase or decrease this number
as needed to account for the size
of the country, population distribution
and density, differing malaria epidemiology
or ecology, and other factors deemed
important. When making such decisions,
emphasis must be placed on the need for
a “manageable” number of sites to ensure
proper monitoring and supervision.
Based on accumulated experience rather
than definitive science, it is recommended
that assessments be conducted at least
once every 24 months; for comparability,
they should always be carried out at the
same time of year. Most programmes
conducting sentinel site surveillance find
it easiest to alternate test sites, for example
testing four sites per year with each site
being assessed every other year.
Monitoring of therapeutic efficacy should
be carried out through a system of well-
selected sentinel sites in order to obtain
consistent longitudinal data and to
document trends. At the initial stage, a
core group of experts (from the national
malaria control programme, ministry of
health, universities, institutes of research,
national reference laboratory) should be
established to coordinate all activities —
training, supervision, collection and
analysis of data — and to forward
recommendations to the drug policy-
makers. This core group should ensure
the quality of laboratory diagnosis at the
sentinel sites and provide continuous
logistic support.
The minimal requirements for establishing
a sentinel site are the availability of trained
and motivated clinical personnel and
microscopists, plus a laboratory equipped
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for blood film examination. The sentinel
site can be at a peripheral facility (true
community-based studies of drug efficacy
are logistically difficult and expensive) or
based at a district-level health facility. Patients
seeking health care at hospitals in urban
settings may have more complex clinical
presentations, may be more likely to have
been referred there because of previous
drug failures, and/or may be more difficult
to find during follow-up. For these
reasons, efficacy monitoring should be
done at the most peripheral sites possible.
The following characteristics should be
considered in the selection of sentinel sites:
– local population density;
– accessibility to the site and feasibility
of close supervision;
– epidemiology of malaria, especially
transmission intensity and seasonality;
– population mobility and migration
(especially in border areas);
– distribution of malaria treatment failures
reported by health information system
(some areas of the country may be
known or suspected to have higher
treatment failure rates).
Sentinel sites should be selected to be
representative of each major epidemiological
stratum into which the country can be
divided. Monitoring can be carried out
either by local personnel at the sentinel
site or by a more specialized mobile
team. The choice will vary with national
resources and the availability of trained
staff at the selected sentinel sites.
Given the importance of the private sector
in drug procurement and distribution in
many countries, and the heterogeneity
of drug resistance, drug utilization and
drug quality studies should be conducted,
whenever feasible, in the areas selected
for sentinel site monitoring. It is likely that
results will not be uniform across sites:
some sites may identify a substantial
deterioration in treatment efficacy while
others continue to record an acceptable
response to the same drug. The programme
should consider questions associated
with this possibility and develop a plan
for responding to it.
For example:
• Can specific treatment guidelines
be targeted to affected areas without
changing national policy or guidelines
as a whole?
• How many sites need to show
unacceptable treatment failures before
national policy or treatment guidelines
are altered?
• What happens when one site in the
system demonstrates a poor level of
treatment success with the existing
first-line drug but the national policy
or treatment guidelines are not altered
because efficacy is higher at the other
sites? At what point does it become
unethical to continue to evaluate that
drug at that site in the future? At what
level of treatment failure would this occur?
What are the implications for routine
treatment of patients at that point?
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Prognostic valuea Frequencya
Children Adults Children Adults
Clinical manifestations
+ (?)b Prostration +++ +++
+++ + Impaired consciousness +++ ++
+++ +++ Respiratory distress (acidotic breathing) +++ +
+ ++ Multiple convulsions +++ +
+++ +++ Circulatory collapse + +
+++ +++ Pulmonary oedema (radiological) +/– +
+++ ++ Abnormal bleeding +/– +
++ + Jaundice + +++
+ + Haemoglobinurea +/– +
Laboratory findings
+ + Severe anaemia +++ +
+++ +++ Hypoglycaemia +++ ++
+++ +++ Acidosis +++ ++
+++ +++ Hyperlactataemia +++ ++
+/– ++ Hyperparasitaemia ++ +
++ ++ Renal impairment  + +++
a On a scale from + to +++; +/– indicates infrequent occurrence.
b Data not available.
1 World Health Organization. Severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and
Hygiene, 2000, 94(Suppl. 1):1–90.
Annex 1
Definition of severe malaria1
Severe manifestations of P. falciparum malaria in adults and children
41Recommendations made by Secretariat Committee on Research Involving Human Subjects(SCRIHS) of the World Health Organization (October 2003).
The consent form has two parts: (a) a statement describing the study and the nature of the
subject’s involvement in it, and (b) a certificate of consent attesting to the subject’s consent.
Both parts should be written in sufficiently large letters and in simple language so that the
subject can easily read and understand the contents. As far as possible, medical terminology
should be avoided in writing up the consent form. It should be written in the prospective
subjects’ mother tongue.
The statement is given or read to each prospective subject. Any questions the subject may
have are then answered and, if consent is given, the certificate is signed by the subject or,
if consent was verbal, by the staff member who provided the information in the presence
of an independent literate witness and ensured that all the information related to the
study was understood. By signing, the staff member confirms that consent was given
freely. A signed certificate must be obtained in this way for each subject admitted to the
study, and a copy must be offered to the subject.
In writing up the statement take note of the following points:
• Indicate that this is a research study to distinguish it from routine care.
• Explain why the study is being done and why the subject has been asked to participate.
• Describe, in sequence, what will happen in the course of the study, giving enough
detail for the subject to gain a clear idea of what to expect.
• Explain whether or not the study procedures offer any benefits to the subject or to others.
• Explain the nature, likelihood and treatment of anticipated discomfort or adverse effects,
including psychological and social risks, if any. Where relevant, include a comparison
with risks posed by standard treatments or drugs, and an indication of whether the drug
or procedure under investigation bears risks equal to, greater than, or less than the standard.
If the risks are unknown or a comparative risk cannot be given it should be so stated.
• Explain what will be done to the “excess” biological samples that will be taken as
part of the research protocol – how soon after the research will they be discarded or
destroyed or for how long will they be stored, how will they be stored and who will
have access to these samples and under what circumstances. Who will have the
responsibility to eventually destroy or discard these samples?
Annex 2
Informed decision making
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• State that all records are to be kept confidential. If absolute confidentiality cannot be
guaranteed, explain why this is so. Explain the extent to which the confidentiality of
subject-specific information will be protected during the study and in any resulting
public disclosures at meetings or in publications. Also state which persons other than the
researchers may have access to the records and/or to whom information may be disclosed.
State where and in what form subject-specific information will be stored, and when, how
and by whom it will be destroyed.
• State that the subject has the right to refuse to participate or withdraw from the study
at any time without in any way affecting his/her current or future care. State what alternative
treatment or procedure would be available for those who choose not to participate in the
study.
• Contact information. The name, address and telephone number must be included on
the form of the person(s) to be contacted by the research subject if they have questions
about, or experience any problems during the course of, the study. These should be
persons who are available on site, intimately involved with the research project and
easily accessible to research participants, not chairpersons of ethics committees or deans
of schools or heads of departments.
• The certificate of consent, which should be a part of the information sheet, should
begin with a brief summary of the main items from the above statement. It should end
with a paragraph such as the following:
I have read the foregoing information, or it has been read to me. I have had the opportunity
to ask questions about it and any questions that I have asked have been answered to my
satisfaction. I consent voluntarily to participate as a subject in this study and understand that
I have the right to withdraw from the study at any time without in any way affecting my
further medical care.
The informed consent document should be signed by the subject or, when the subject
is illiterate, by an independent (preferably literate) witness who provides the informa-
tion, and who ascertains that it was understood and confirms that consent was given
freely. Whenever possible, the witness should be selected by the subject and he/she
should not be connected with the research team. Whenever feasible, the recruitment
of illiterate subjects should take place in the presence of a literate witness.
• Statement of Consent for Storage and Future Use of Leftover Specimens and Signatures.
If the protocol calls for the storage and future use of specimens, the consent form should
provide the option of either immediate destruction or maintenance and use of specimens
for future research on either the same subject or for future research of any type. This
section should also provide the option for specimens to either be destroyed after
a certain period of time or kept indefinitely, as well as the option for the participant’s
identity to either be removed or kept with the leftover specimens.
43• Detection of chloroquine
Chloroquine and its metabolite can be detected by an adapted Saker–Solomons test.1 For
this test, 2 ml of urine are mixed in a glass tube with 1 ml of phosphate buffer, pH 8.0,
and 0.2 ml of tetrabromophenolphthalein ethyl ester (TBPEE). The tube is capped,
vigorously hand-shaken for about 15 seconds, and left to stand for about 15 minutes to
allow phase separation before the results are read. A yellow-green colour of the chloroform
layer indicates a negative test for chloroquine and metabolites; a red to purple colour of
the organic layer indicates a positive result — the shade depends on the concentration
of chloroquine and/or metabolites. Comparing the colour obtained in the patient’s test
with standards containing known concentrations of chloroquine provides semiquantitative
results. Other drugs can show cross-reactivity with chloroquine in the Saker–Solomons
tests, including quinine, proguanil and, to a lesser extent, mefloquine and pyrimethamine.











 and 500 ml distilled water.
– TBPEE is prepared by dissolving 50 mg TBPEE in 100 ml chloroform, then shaking
this mixture with 10 ml of 2 mol/litre HCl.
• Detection of sulfonamides
Lignin test
For this test, two drops of urine are placed on a strip of unbleached paper (blank newspaper
or unbleached paper towel). One drop of 10% hydrochloric acid (3 mol/litre) is added
to the centre of the moistened area. A yellow or orange colour appearing within 20 seconds
denotes the presence of sulfonamides. Although not highly sensitive, the lignin test is
adequate for the purposes of this protocol. This test also cross-reacts with other drugs.
Qualitative colorimetric test for sulfonamides in urine
This test is based on the extraction of sulfadoxine (or other sulfonamide drugs) from
urine into ethyl acetate followed by the formation of a violet-red Shiff base upon
addition of acidic methanolic p-dimethylaminocinnamaldehyde. The intensity of the
colour is proportional to the sulfonamide concentration in the sample. Semi-quantitative
estimates can be made by comparing colour intensities in unknown samples with those
in urine samples containing known concentrations of sulfonamide.
Annex 3
Detection of antimalarial drugs in urine
ANNEX 3 – DETECTION OF ANTIMALARIAL DRUGS IN URINE
1 Mount DL et al. Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for
chloroquine and its metabolites in urine. Bulletin of the World Health Organization, 1989, 67:295–300.
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Reagents
1. Colour reagent solution: 0.3% (m/v) p-dimethylaminocinnamaldehyde (DMACNA)









 + 100 ml methanol)











 dissolved and diluted to 500 ml with distilled water
3. SAG-10 silicone antifoam emulsion diluted 50/50 with water
4. Ethyl acetate
5. Sulfadoxine standard: 1mg/ml in ethanol
Procedure
1. Prepare a standard curve by adding appropriate volumes of standard sulfadoxine
solution to 2 ml of drug-free urine according to table below:





2. Using a pipette, add 2 ml of patient’s urine to 0.5 ml ethyl acetate and 0.5 ml buffer
solution in a 1-dram clear glass screw-cap vial. Cap the vial and invert 20 times. After the
ethyl acetate phase rises to the top, add one drop of SAG-10 defoamer to the acetate
phase to break the emulsion formed during inversion. If needed, the vial can be swirled
gently to help break up the emulsion. After the ethyl acetate layer has cleared, add 3 drops
of the colour reagent to the top of the layer without agitation. The formation of a red-purple
ring at the top of the ethyl acetate layer indicates the presence of sulfadoxine. For semi-
quantitative results, compare the intensity of the red-purple colour with that produced
by standards.
Notes:
1. The colour will fade slowly with time but immediately upon significant agitation or
mixing. Fresh standards should therefore be prepared frequently.
2. Vials may be precharged with ethyl acetate and buffer solution.
3. Occasionally, a substance may be present in urine that reacts with the colour reagent
at a slower rate than sulfonamide drugs, giving a green-blue colour. This slower colour
change does not affect the results of the test.
4. Store colour reagent in a refrigerator to extend its shelf life. Degradation is indicated
by the loss of the yellow-orange colour of the solution.
45• Other tests
Dipstick tests based on a specific reaction of antimalarial drug with monoclonal
antibodies have been developed for chloroquine, pyrimethamine, quinine and
artemisinin compounds. These tests are more sensitive than the classic colorimetric
tests and their results are well correlated with the results of high-performance liquid
chromatography (HPLC). HPLC can also assess the presence of antimalarial drugs
in biological fluids but the method requires well-equipped laboratories and is beyond
the scope of this protocol.
ANNEX 3 – DETECTION OF ANTIMALARIAL DRUGS IN URINE
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If the proportion of treatment failure is already known from earlier studies, the required
sample size can be calculated by classical statistical methods for estimating the
population proportion. Three pieces of information are needed to determine the proper
sample size for estimating a population proportion — the expected population
proportion of clinical failures (P), the confidence level (usually 95%), and the precision
(d) (usually between 5% and 10%). In order for the sample to be representative, a
minimum of 50 patients should always be included.
If the proportion of treatment failure is unknown, a value of P = 0.50 is recommended,
since the sample size will be largest and will provide enough observations, irrespective
of the actual failure rate value of the true population. Assuming a simple random sample
of a community is to be selected, the sample size must be 96 in order to achieve 10%
precision with 95% confidence level.
Example
A health department wishes to undertake a therapeutic efficacy test of chloroquine to
estimate the prevalence of clinical failure among the local population. Chloroquine is the
first-line treatment, and routine follow-up of treated cases suggests that the prevalence
of clinical failure is somewhere between 20% and 25%. Dissatisfaction with chloroquine
is also reported among the population. How many subjects should be included in the
sample so that there is a good chance of the study estimating prevalence to within 10
percentage points of the true value with 95% confidence?
Anticipated population proportion of clinical failures (P): 20%
Confidence level: 95%
Precision (d): 10 percentage points
The table shows that for P = 0.20 and d = 0.10 a sample size of 61 would be needed.
Sample size must be adjusted for the follow-up losses and withdrawals (expected to be
10% in a study with 14 days follow-up and 20% in studies with longer follow-up).
         n = (1 + 0.10) x 61 = 67    or n = (1 + 0.20) x 61 = 73
It is recommended that all the criteria used for the sample size determination are
specified when the study results are reported.
a In order to be representative, a minimum of 50 patients should always be included.
Annex 4
Minimum sample size
Anticipated population proportion (P) – Confidence level: 95%
d 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50
0.05 73 138 196 246 288 323 350 369 380 384
0.10 18a 35a 49a 61 72 81 87 92 95 96
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Annex 5
Example case record forms – (a) 28-day follow-up in low to moderate transmission area



















   




   
   
   
































   







   








   
   





























































   
   
   
   
   
   






































































































































































































































































































































































































































































































































(b) 14-day follow-up in high transmission area
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In view of the need for supervision of all treatment doses given during this evaluation,
the therapeutic efficacy test system is most suitable for treatment regimens requiring
administration of a single dose or of a single daily dose given over 3 days. If drugs have
to be given more than once a day, it may be necessary to hospitalize the patients during
treatment to ensure that all doses are given correctly. This therapeutic efficacy test is
intended only for evaluating the treatment of uncomplicated falciparum malaria, and
therefore involves only the orally administered drugs. Detailed information on the
various drugs to be used, including doses according to body weight, may be found in
the WHO document The use of antimalarial drugs.1
Drugs and formulations
The drugs employed for therapeutic efficacy testing should be from a reliable, quality-
controlled batch; WHO can provide assistance in the procurement of drugs. Drugs
should not be used beyond the expiry date mentioned on the package. For purposes
of later identification, the manufacturer and batch number of the administered drug
should be recorded on the patient record form.
This assessment procedure is appropriate for any standard malaria treatment, including
combination approaches. Generally, drugs in current use and those that have been
identified as possible alternatives are routinely tested. Protocols intended for assessing
new malaria treatments, including new combinations of antimalarial drugs, should be
approved by a competent, independent ethical review authority to ensure the protection
of patient safety.
The following drugs and formulations are most often evaluated with this efficacy test:
• CHLOROQUINE
Tablets: 100 mg base or 150 mg base (as phosphate or sulfate)
Syrup: 50 mg / 5ml (as phosphate or sulfate)
Treatment with chloroquine
Treatment with chloroquine consists of a 3-day course with the following doses:
Day 0 10 mg base/kg body weight
Day 1 10 mg base/kg body weight
Day 2  5 mg base/kg body weight
In practice, it is difficult to divide the tablets into fractions containing exactly the desired
weight-based dose. A range of weight groups are therefore used with the dose regimen
adjusted to the nearest manageable fractions of the tablets. The bitter taste of
chloroquine often makes it hard to treat infants and young children successfully.
Crushing the tablets and mixing them with a little water and sugar on a spoon can often
solve this problem; for children with a marked tendency to vomit, the crushed tablets
can be mixed with banana or other locally available foods.
Annex 6
Treatments
1 The use of antimalarial drugs. Report of a WHO informal consultation. Geneva, World Health Organization, 2001
(document WHO/CDS/RBM/2001.33).
51• AMODIAQUINETablets: 153 mg base (as hydrochloride)
Tablets: 200 mg and 600 mg base (as hydrochloride) are available but difficult to divide
Treatment with amodiaquine
Amodiaquine treatment follows the same dose regimen as that given for chloroquine
above. However, doses of between 25 and 35 mg amodiaquine base/kg over 3 days
have been used safely. The most practical dose regimen is 30 mg base/kg divided
equally over 3 days.
• SULFONAMIDE–PYRIMETHAMINE COMBINATIONS
Tablets: 500 mg sulfadoxine + 25 mg pyrimethamine
Tablets: 500 mg sulfalene + 25 mg pyrimethamine
Treatment with sulfonamide–pyrimethamine combinations
Sulfadoxine–pyrimethamine and sulfalene–pyrimethamine are given as a single dose
equivalent to 1.25 mg pyrimethamine/kg body weight (up to a maximum adult dose
of 3 tablets). If the body temperature exceeds 38.5 °C, the patient should receive one
dose of paracetamol immediately and another dose to be taken later at home if the
fever persists. Parents/guardians should be instructed to use tepid sponging to reduce
fever during the initial 24 to 48 hours. Failure to discuss this issue may lead to
perception that treatment is not effective, and patients (or parents/guardians) may
seek alternative medication, interfering with the study protocol.
• MEFLOQUINE
Tablets: 250 mg base (as hydrochloride).
Note: The formulation available in USA contains 228 mg mefloquine base.
Treatment with mefloquine
The standard adult dose for treatment of uncomplicated malaria is 25 mg base/kg
of body weight. Bioavailability is improved if the patient drinks water or takes some
food before drug administration. Febrile children are more likely to have drug-related
vomiting, which can be reduced by giving an antipyretic. Tolerance of mefloquine is
substantially improved if the drug is given as a split dose with an interval of 6–24 hours.
• ARTEMISININ DERIVATIVES
Treatment with artemisinin compounds and combinations:
Treatment with artemisinin derivatives alone lasts longer than 3 days and is therefore
beyond the scope of this protocol. However, artemisinins (particularly artesunate)
used in combination with other antimalarial drugs (such as amodiaquine, sulfadoxine-
pyrimethamine, mefloquine or lumefantrine) are commonly assessed. The fixed-dose
combination of artemether and lumefantrine is given twice daily over 3 days and
would probably require hospitalization to ensure correct dosing.
ANNEX 6 – TREATMENTS
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When used in combination with other antimalarial drugs for uncomplicated malaria,
artesunate is given at a dose of 4 mg/kg once daily for 3 days. The treatment schedules
for the partner drug (whether amodiaquine, sulfadoxine–pyrimethamine or mefloquine)
are the same as outlined above. For a combination of artesunate and mefloquine, splitting
the mefloquine dose on the second and third day improves tolerability. Additional
information regarding proper dosing of other artemisinin-containing drug combinations
can be found in the WHO document The use of antimalarial drugs.1
Other medications
The administration of paracetamol on Day 0, Day 1 and Day 2 is permissible if the
patient’s condition warrants it. If, during follow-up, infections other than malaria require
the administration of drugs with antimalarial activity (such as co-trimoxazole,
tetracycline or doxycycline), the patient should be excluded from the study. Patients
given tetracycline as eye ointment should not be excluded.
1 Ibid.
53Recommendations made by working groups during the Workshop on the markers ofantimalarial drug resistance: practical, clinical, and epidemiological applications,
Geneva 14–16 June 1999.
Several methods are available for collecting infected blood for molecular analysis.
Workshop participants have the most experience with IsoCode® stick (Schleicher &
Schuell) and 3MM® filter paper (Whatman). Extraction techniques of parasite DNA are
similarly simple for both types of sample collection. IsoCode® sticks are more expensive
but offer the advantages of standardized sample size and prepackaged storage units.
Rigorous direct comparisons of DNA yield have not been undertaken. All samples
should be clearly labelled with permanent ink with the date, study identification
number, and other pertinent information such as post-treatment day.
IsoCode® sticks should be stored in the individual sealed plastic bags with desiccant
provided by the manufacturer. Sites opting to use 3MM® paper should obtain similar
small zip-lock bags, such as those used by pharmacies in many countries for dispensing
pills, and store filter paper individually with desiccant pouches, which can be obtained
in bulk and inexpensively. Storage conditions should protect samples from extremes
of temperature and humidity. When such room temperature conditions are not possible,
for example in extremely humid environments where air-conditioning is not available,
storage in a refrigerator or freezer may be considered, but great care must be taken to
protect samples from frost and moisture.
Annex 7
Sampling and storing filter paper for molecular marker studies
ANNEX 7 – SAMPLING AND STORING FILTER PAPER FOR MOLECULAR MARKER STUDIES
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NOTES: Parentheses denote conditional or optional activities. For example, treatment on
Days 1 and 2 would occur only for drugs requiring 3-day dosing. On Day 1, the patient
should be examined for parasitaemia if she or he has any danger signs. Rescue treatment
could be given on any day, provided that the patient met the criteria for treatment
failure. Extra days are any days other than regularly scheduled follow-up days when the
patient returns to the facility because of recurrence of symptoms. On extra days, blood
slides may or may not be routinely taken; in areas of intense transmission, slides are
typically obtained on extra days only if there is measured fever (or at the request of the
clinical staff for reasons of patient safety).
Annex 8
Basic follow-up schedule
Day 0 Day 1 Day 2 Day 3 Day 7 Day14 (Day 21) (Day 28) (Any other day)
PROCEDURES
Clinical
X X X X X X X X Xassessment
Temperature X X X X X X X X X
Blood slide for
X (X) X X X X X X (X)parasites count
Haemoglobin/
haematocrita (X) (X) (X) (X)
Urine sample (X)




Drug to be tested X (X) (X)
Rescue treatment (X) (X) (X) (X) (X) (X) (X) (X)
a Erythrocyte volume fraction.
55Day 0:Clinical assessment — referral in case of severe malaria/danger signs
Measurement of axillary temperature
Parasitological assessment
Informed consent — enrolment
Measurement of weight (and height) — treatment, first dose
Optional: haemoglobin/haematocrit, urinary test, blood sampling for PCR
Day 1:
Clinical assessment — referral in case of severe malaria/danger signs
Measurement of axillary temperature
Parasitological assessment in case of severe malaria/danger signs
Treatment, second dose or alternative treatment in case of early treatment failure
Day 2:
Clinical assessment — referral in case of severe malaria/danger signs
Measurement of axillary temperature
Parasitological assessment
Treatment, third dose or alternative treatment in case of early treatment failure
Day 3, Day 7, Day 14, Day 21 and Day 28:
Clinical assessment — referral in case of severe malaria/danger signs
Measurement of axillary temperature
Parasitological assessment
Alternative treatment in case of treatment failure
Optional: haemoglobin/haematocrit (Day 14, Day 28), blood sampling for PCR
(any other day on or after Day 14 in case of failure)
Any other day:
Clinical assessment — referral in case of severe malaria/danger signs
Measurement of axillary temperature
Parasitological assessment
Alternative treatment in case of treatment failure
ANNEX 8 – BASIC FOLLOW-UP SCHEDULE
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INTENSE TRANSMISSION AREA LOW TO MODERATE TRANSMISSION AREA
Early Treatment Failure (ETF)
Late Treatment Failure (LTF)
Adequate Clinical and Parasitological Response (ACPR)
ETF
• Development of danger signs or severe
malaria on Day 1, Day 2 or Day 3, in the
presence of parasitemia
• Parasitaemia on Day 2 higher than Day 0
count irrespective of axillary temperature
• Parasitemia on Day 3 with axillary
temperature ≥  37.5 °C
• Parasitemia on Day 3 ≥ 25 % of count on
Day 0
Late Clinical Failure (LCF)
• Development of danger signs or severe
malaria after Day 3 in the presence of
parasitemia, without previously meeting
any of the criteria of Early Treatment Failure
• Presence of parasitemia and axillary
temperature ≥ 37.5°C on any day from
Day 4 to Day 14, without previously
meeting any of the criteria of Early
Treatment Failure
Late Parasitological Failure (LPF)
• Presence of parasitemia on Day 14 and
axillary temperature < 37.5°C, without
previously meeting any of the criteria of
Early Treatment Failure or Late Clinical Failure
ACPR
• Absence of parasitemia on Day 14
irrespective of axillary temperature without
previously meeting any of the criteria of
Early Treatment Failure or Late Clinical
Failure or Late Parasitological Failure.
ETF
• Development of danger signs or severe
malaria on Day 1, Day 2 or Day 3, in the
presence of parasitemia;
• Parasitaemia on Day 2 higher than Day 0
count irrespective of axillary temperature;
• Parasitemia on Day 3 with axillary
temperature ≥ 37.5 °C;
• Parasitemia on Day 3 ≥ 25 % of count on
Day 0.
Late Clinical Failure (LCF)
• Development of danger signs or severe
malaria after Day 3 in the presence of
parasitemia, without previously meeting
any of the criteria of Early Treatment Failure
• Presence of parasitemia and axillary
temperature ≥ 37.5 °C (or history of fever)
on any day from Day 4 to Day 28,
without previously meeting any of the
criteria of Early Treatment Failure
Late Parasitological Failure (LPF)
• Presence of parasitemia on any day from
Day 7 to Day 28 and axillary temperature
< 37.5 °C, without previously meeting any
of the criteria of Early Treatment Failure or
Late Clinical Failure
ACPR
• Absence of parasitemia on Day 28
irrespective of axillary temperature without
previously meeting any of the criteria of
Early Treatment Failure or Late Clinical
Failure or Late Parasitological Failure.
Annex 9
Classification of treatment outcomes {{
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Annex 10
Calculating Kaplan-Meier survival curves by hand
D N TF ex IR SCI FCI
0 65 0 0 1.000 1.000 0
1 65 0 0 1.000 1.000 0
2 65 2 0 0.969 0.969 0.031
3 63 2 1 0.968 0.938 0.062
4 60 0 0 1.000 0.938 0.062
5 60 0 0 1.000 0.938 0.062
6 60 0 0 1.000 0.938 0.062
7 60 4 2 0.931 0.873 0.127
8 54 0 0 1.000 0.873 0.127
9 54 0 0 1.000 0.873 0.127
10 54 0 0 1.000 0.873 0.127
11 54 2 0 0.963 0.841 0.159
12 52 0 0 1.000 0.841 0.159
13 52 0 0 1.000 0.841 0.159
14 52 5 0 0.904 0.760 0.240
Total 15 3
D = day of test
N
D







 where D is day of test and D–1 is the day before
TF = incident cases of therapeutic failure
ex = excluded due to loss to follow-up, withdrawal or protocol violation
IR
D





















 where D is day of test and D–1 is the day before,
e.g. for calculating SCI on Day 14, use IR Day 14 and SCI Day 13
FCI
D
= cumulative incidence of therapeutic failure
= 1 – SCI
D
ANNEX 10 – CALCULATING KAPLAN-MEIER SURVIVAL CURVES BY HAND
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Deionized water 1000 ml
Method. Autoclave or filter-sterilize (0.2 µm pore). Sterile buffer is stable at room
temperature for one year.
• Working Giemsa buffer (0.0067 mol/litre, pH 7.2)
Stock Giemsa buffer 10.0 ml
Deionized water 990.0 ml
Method. Check pH before use: it should be 7.2. This working buffer solution is stable at
room temperature for about one month.
• Triton X-100 (5%) – if available
Deionized water (warmed to 56 °C) 95.0 ml
Triton X-100 5.0 ml
Method. Prewarm the deionized water and slowly add the Triton X-100, swirling to mix.
• Stock Giemsa stain
Note: Giemsa stain is available commercially, but the following formulation gives more
constant results and does not expire.
Glass beads, 3.0 mm 30.0 ml
Absolute methanol, acetone-free 270.0 ml
Certified Giemsa stain powder 3.0 g
Glycerol 140.0 ml
Method. Put the glass beads and the other ingredients, in the order listed, into a clean and dry
500-ml brown-glass bottle. Screw cap onto the bottle tightly. Place the bottle at an angle on
a shaker and shake moderately for 30–60 minutes daily, for at least 14 days. Kept tightly
closed and free of moisture. Stock Giemsa stain is stable indefinitely at room temperature
and, in fact, will improve with age. Before use, shake the bottle. Filter a small amount of this
stock stain through Whatman No.1 filter paper into a clean test-tube. Pipette from this tube
to prepare the working Giemsa stain in order to keep the stock stain uncontaminated.
• Working Giemsa stain (2.5%)
Working Giemsa buffer 39 ml
Giemsa stain stock 1 ml





• A person may attain adolescence before infection is acquired and may escape
altogether
Moderate transmission
• Maximum incidence occurs in childhood and adolescence, though still not unusual
for adult life to be attained before acquiring infection
High transmission
• By late infancy or early childhood practically all are infected. Little acute illness
in adolescents and still less in adults
• Most individuals acquire infection in early infancy, but acute manifestations are
less frequent in childhood and are unusual in adults
Annex 12
Classification of malaria endemicity
Type Spleen rates Parasite rates
Hypoendemicity 0–10% in children Less than 10% in children
aged 2–9 years aged 2–9 years but may be
higher during part of the year
Mesoendemicity 11–50% in children 11–50% in children
aged 2–9 years aged 2–9 years
Hyperendemicity Constantly over 50% in children Constantly over 50%
aged 2–9 years, adult spleen rate in children aged 2-9 years
also high (over 25%)
Holoendemicity Constantly over 75% in children Constantly over 75%
aged 2–9 years, adult spleen in infants aged 0–11 months
rate low
ANNEX 12 – CLASSIFICATION OF MALARIA ENDEMICITY
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All equipment and supplies should be of good quality and — while not in use — stored
in a way that prevents deterioration. In many countries, the equipment should be
available from the country’s health services. However, where these supplies and
equipment are not readily available, budgetary provision must be made.
EQUIPMENT REQUIRED BY ONE STUDY TEAM
ITEM NUMBER REQUIRED
(1) Clinical
Stethoscope 1 (per clinician)
Balance 1 (per clinician)
Height gauge 1 (per clinician)
Fever thermometer, electronic 3 (per clinician)
Teaspoons 2 (per clinician)
(2) Laboratory
Microscope, binocular, w. illumination 1
(or microscope with mirror for situations without electricity)
Tally counter 2
Hairdryer (for humid areas and seasons) 1
Laboratory timer 2
Slide box, for vertical storage 10
Slide box, for horizontal storage, WHO type 2
Slide tray, cardboard 2
Drying rack, wood for slides 1
Staining jar, Coplin or horizontal 3
Bottle, screw-cap, plastic, 500 ml 2
Bottle or jerrycan, screw-cap, plastic, 5 l 2
Measuring cylinder, plastic, 500 ml 2
Measuring cylinder, plastic, 10 ml 2
Dropping-bottle, plastic or glass, 50 ml 2
Glass rod, 50 cm, for quick staining 4
(3) General
Clipboard 1 (per clinician)
File jacket, stiff card 10
Transport box 3
SUPPLIES REQUIRED PER 100 PATIENTS
ITEM NUMBER REQUIRED
(1) Clinical
Test drug 150 courses/doses
Next-line alternative drug 100 courses/doses
Third-line drug, if applicable 50 courses/doses
Quinine for injection 20 ampoules
Co-trimoxazole 200 tablets
Annex 13





Injection syringes, sterile, disposable, 2 ml 20
Injection syringes, sterile, disposable, 5 ml 20
Injection needles for above, disposable, no.12 or 14 40
Spare battery, for electronic thermometer 3
Plastic cups 3
(2) Patient incentives
Sweets (bonbons, candy), pack of 100 10
Biscuits, packs of ~50 10
Sugar 1 kg
(3) Laboratory
Microscope slides, frosted edge, pack of 100 15
Lens tissue, pack of 100 2
Haemolancets, pack of 100 8
Swabs, alcohol (70 %), pack of 100 8
Rubber gloves, disposable, medium size 50 pairs
Rubber gloves, disposable, large size 50 pairs
Pipettes, transfer, disposable, 5 ml, pack of 100 1
Pipettes, transfer, disposable, 1 ml, pack of 100 1
Glass-writing pen, permanent, xylene-proof 5
Plasticine 200 g
Buffer tablets, pH 7.2  20
Immersion oil, bottle of 50 ml 1
Xylene, bottle of 500 ml 1
Methanol, bottle of 500 ml 1
Giemsa stain stock solution, bottle of 500 ml 1
Distilled water 20 litres
Cotton wool, pack of 500 g 2
Syringe, plastic, 10 ml 2
(4) General
Logbook, A4, 100 pp. 1 (per clinician)
Notepad, A4 4
Ball-point pen, black/blue 10
Ball-point pen, red 10
Adhesive tape, roll, 30 m 2
Toilet paper, roll 10
Patient forms 150
Patient cards 150
Laboratory form (microscopy and haematology) 700
ANNEX 13 – STANDARD MATERIAL REQUIRED FOR THE THERAPEUTIC EFFICACY TEST
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This annex indicates the essential sections of a protocol for monitoring the efficacy of
antimalarial drugs for the treatment of uncomplicated falciparum malaria according to
the epidemiological setting. For clarity, consistency and thoroughness, all of the following











• Malaria situation in the country





• Description of the site(s)
• Timing
• Composition of the team






Sample table of contents of a protocol
– High transmission area
◊ aged between 6 and 59 months
◊ mono-infection with P. falciparum
◊ Parasitaemia in the range 2000
to 200 000/µl
◊ axillary temperature ≥ 37.5 °C
◊ able to come for the stipulated
follow-up visits; easy access to
the health facility
◊ informed consent of parent/guardian
– Low to moderate transmission area
◊ patients aged above 6 months
◊ mono-infection with P. falciparum
◊ parasitaemia in the range of 1000
to 100 000/µl
◊ axillary temperature ≥ 37.5 °C
or history of fever during the
previous 24 hours
◊ able to come for the stipulated
follow-up visits; easy access to
the health facility
◊ informed consent by the patient
or by parent/guardian for children
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• Exclusion criteria
◊ presence of one or more of the general danger signs or any sign of severe
or complicated malaria
◊ presence of mixed infection
◊ presence of severe malnutrition
◊ presence of febrile conditions caused by diseases other than malaria
◊ presence of a severe disease
◊ contraindications related to the antimalarial drugs used, especially history of allergy
◊ pregnancy (in low to moderate transmission area only)
• Sample size
Estimation of the population proportion at a confidence level of 95%
Anticipated population proportion (P)
d 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50
0.05 73 138 196 246 288 323 350 369 380 384
0.10 50 50 50 61 72 81 87 92 95 96
SCREENING AND ENROLMENT PROCEDURES
ETHICAL ISSUES
• Approval by ethical committee
• Informed consent
LABORATORY EXAMINATIONS
• Blood smear for malaria diagnosis
• Haematological assessment (haemoglobin/haematocrit) (optional)
• Urinary test (optional)
• PCR (mandatory in high transmission area if 28-day follow-up)
• Pregnancy test (if adults included)
FOLLOW-UP PROCEDURE
ANNEX 14 – SAMPLE TABLE OF CONTENTS OF A PROTOCOL
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ASSESSMENT AND MONITORING OF ANTIMALAIRAL DRUG EFFICACY FOR THE TREATMENT OF UNCOMPLICATED FALCIPARUM MALARIA
END-POINTS
All patients must be classified as Adequate Clinical and Parasitological Response,
Late Parasitogical Failure, Late Clinical Failure, Early Treatment Failure, Loss to Follow-up,
or Withdrawn
High transmission areas
• Early Treatment Failure (ETF)
– Development of danger signs or severe malaria on Day 1, Day 2 or Day 3, in the
presence of parasitaemia
– Parasitaemia on Day 2 higher than Day 0 count irrespective of axillary temperature
– Parasitaemia on Day 3 with axillary temperature ≥ 37.5 °C
– Parasitaemia on Day 3 ≥ 25% of count on Day 0
• Late Clinical Failure (LCF)
– Development of danger signs or severe malaria after Day 3 in the presence of
parasitaemia, without previously meeting any of the criteria of Early Treatment Failure
– Presence of parasitaemia and axillary temperature ≥ 37.5 °C on any day from Day 4 to
Day 14 (Day 281), without previously meeting any of the criteria of Early Treatment Failure
• Late Parasitogical Failure (LPF)
– Presence of parasitaemia on Day 14 (or Day 281) and axillary temperature < 37.5 °C,
without previously meeting any of the criteria of Early Treatment Failure or Late Clinical
Failure
• Adequate Clinical and Parasitological Response (ACPR)
– Absence of parasitaemia on Day 14 (or Day 281) irrespective of axillary temperature,
without previously meeting any of the criteria of Early Treatment Failure or Late Clinical
Failure or Late Parasitological Failure
1 If 28 day follow-up
65Low to moderate transmission areas
• Early Treatment Failure (ETF)
– Development of danger signs or severe malaria on Day 1, Day 2 or Day 3, in the
presence of parasitaemia
– Parasitaemia on Day 2 higher than Day 0 count irrespective of axillary temperature
– Parasitaemia on Day 3 with axillary temperature ≥ 37.5 °C
– Parasitaemia on Day 3 ≥ 25 % of count on Day 0
• Late Clinical Failure (LCF)
– Development of danger signs or severe malaria after Day 3 in the presence of
parasitaemia, without previously meeting any of the criteria of Early Treatment Failure
– Presence of parasitaemia and axillary temperature ≥ 37.5 °C on any day from Day 4
to Day 28, without previously meeting any of the criteria of Early Treatment Failure
• Late Parasitogical Failure (LPF)
– Presence of parasitaemia on any day from Day 7 to Day 28 and axillary temperature
< 37.5 °C, without previously meeting any of the criteria of Early Treatment Failure
or Late Clinical Failure
• Adequate Clinical and Parasitological Response (ACPR)
– Absence of parasitaemia on Day 28 irrespective of axillary temperature without
previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure
or Late Parasitological Failure
ANNEX 14 – SAMPLE TABLE OF CONTENTS OF A PROTOCOL
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ASSESSMENT AND MONITORING OF ANTIMALAIRAL DRUG EFFICACY FOR THE TREATMENT OF UNCOMPLICATED FALCIPARUM MALARIA
Reasons for withdrawal of a patient from the study, including voluntary and involuntary
withdrawal, and protocol violation
– Withdrawal of consent
– Failure to complete the treatment
– Persistent vomiting of the treatment
– Severe side-effects necessitating hospitalization
– Occurrence during the follow-up of concomitant disease that would interfere with
a clear classification of the treatment outcome
– Reinfection with P. falciparum during the follow-up
– PCR unclassifiable results
– Detection of another malaria species infection during the follow-up
– Antimalarial (or antibiotics with antimalarial activity) treatment administered by a third
party or self-medication with antimalarial (or antibiotics with antimalarial activity)
– Failure to attend all the scheduled visits
– Erroneous inclusion of a patient outside of the inclusion/exclusion criteria
– Severe malaria occurring at Day 0
– Misclassification of a patient due to a laboratory error (parasitaemia) leading to
the administration of the rescue treatment
67ANALYSIS• Per protocol, life table
QUALITY CONTROL
• Temperature, body weight, slides, drugs, data (case record form, data entry in
computer, analysis), laboratory assessments
DISSEMINATION OF THE DATA




• Definition of severe malaria
• Follow-up schedule
• Dosing table for antimalarial drugs
• Screening form
• Case record form
• Informed consent (translated in prospective subjects’ mother tongue)
ANNEX 14 – SAMPLE TABLE OF CONTENTS OF A PROTOCOL
